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TOWARDS MORE RATIONAL PRESCRIBING
The articles in JUMMEC deal with a wide variety of
issues; foremost amongst them, is the discussion on
the rational use of drugs in treating many illnesses and
medical conditions.
Certainly, drug therapy is critical for the treatment of
many illnesses and conditions but in the present
climate of rising cost of care and limited resources, we
should ask ourselves if we are getting value for our
money; in other words, there should be more rational
use of drugs. Antibiotics are amongst one of the 
more frequently prescribed drugs. In fact, it had been
reported to account for as much as 50% of some
hospital pharmacy budgets. The widespread use of
antibiotics had lead to the emergence and spread of
microbes, that are resistant to cheap and effective
“first-line” drugs.
Resistance to antimicrobials is a natural biological
phenomenon – a case of survival if you like. Factors
that contribute to this emergence of drug resistance
include human practices ranging from poor prescribing,
unnecessary or not indicated use, under-dosing or
using for too short a duration, poor compliance on the
part of the patient, as well as veterinary prescribing in
animal husbandry.
As seen from the paper on antimicrobial susceptibility
of Pseudomonas aeruginosa, susceptibility of this orga-
nism to the newer, more expensive antimicrobials has
already been compromised. Fortunately, community-
acquired Pseudomonas aeruginosa infections are still
100% susceptible. That being the case, every effort
should be made to prevent further emergence of more
drug-resistant organisms.
This problem of antimicrobial resistance has reached
an alarming stage of global importance, that in
September 2001, WHO launched the first global
strategy to combat the problem of drug resistance.
The University of Malaya Medical Centre should be
commended for having developed an antibiotic guide-
line for use in the hospital – to enhance and encou-
rage more rational antibiotic prescribing.
Besides drug resistance, drug cost is also a matter of
huge concern in any health care organization. Here
again, it is timely that efforts have been made to relook
at the cost of drugs. An original article compared the
use of risperidone with olanzapine in the treatment of
schizophrenia.
Besides cost being the underlying principle in drug
prescribing, efficacy and safety should be important
considerations as well. While steroids would seem a
less expensive choice as an agent for immunosup-
pression after renal transplantation, there are other
alternatives, albeit more expensive, which would be
safer, less toxic and more efficacious. In the review
article, discussion was centred on the withdrawal or
avoidance of use of steroids after renal transplantation.
Complementary medicine is currently in vogue al-
though much of it has not been well understood nor
has it been scientifically studied. Substances that are
ingested, either supplements or remedies, have not
been subjected to the same rigorous processes that
new drugs have to undergo when seeking registration.
The paper on cytoprotective effect of honey with
extracts of Chromolaena odorata L. a herb, is certainly
worth further reading. Obviously for such herbs to 
be deemed efficacious and of medicinal value would
require well-designed, blinded randomized-control
trials performed on humans.
Cardiovascular disease (CVD) is very prevalent in
Malaysia. It is still the number one cause of medically
certified deaths in our country. Interest in aetiological
factors, one of which is obesity, is being extensively
studied. It is interesting to note in the paper, “Body 
fat comparison between basketball and netball players
in Malaysia” that even amongst national athletes, in
particular, female basketball and netball players, their
average percentage of body fat, is higher than the
desired average for elite sportsmen.
Angina is one of the presenting symptoms of coronary
heart disease. However, trying to reach a diagnosis of
angina could be quite complicated and fraught with
uncertainties.The use of simple neural network archi-
tecture to diagnose angina was discussed in some
detail in this issue.
While CVD is the number one killer in Malaysia, deaths
due to road traffic accidents (RTA) are not far behind.
In fact, year after year, we read about the large number
of RTA deaths. There could be many contributing
factors to this, and poor visual acuity is certainly a
possible cause. It would appear from the paper on
visual defects amongst commercial vehicles drivers that
indeed visual defects are under-diagnosed. Greater
efforts should be made to detect visual defects, not
only amongst commercial vehicle drivers but all
drivers, too.
Finally, it is encouraging to note that maternal mortality
in Malaysia had declined very significantly over the last
50 years. However, this is no reason to rest on our
laurels. It had been discussed in “Measuring maternal
mortality in Malaysia” that we should be looking at the
lifetime risk of maternal mortality and not at maternal
mortality ratio alone. More importantly, the question
is, could maternal mortality be further reduced. And
now, with more interest in maternal mortality and so
many clinical trials being conducted that include a
significant number of women, it can be said that the era
of women, has finally arrived.
Chia Yook Chin MBBS FRCP, FAFPM (Hon)
Professor and Senior Consultant
Department of Primary Care Medicine
Faculty of Medicine, University of Malaya
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2REVIEW
STEROID WITHDRAWAL OR AVOIDANCE IN 
RENAL TRANSPLANT RECIPIENTS
Introduction
Steroids remain an important component of maintenance
immunosuppression after renal transplantation.While
still incompletely understood, recent discoveries have
provided insights into their mechanisms of action (1).
Their anti-inflammatory action is partly due to the
sequestration of CD4+ lymphocytes in the reticulo-
endothelial system. Steroids bind to intracellular
receptors and the resulting steroid-receptor complex
alters the transcription of cytokines by binding to
glucocorticoid response elements on DNA. Trans-
cription factors whose actions are altered by gluco-
corticoids include activating protein-1 (AP-1) and
nuclear factor-κB (NF-κB).The main cytokines whose
production by antigen-presenting cells is inhibited by
steroids are interleukin-1 (IL-1), required for helper T-
cell activation, and IL-6, required for B-cell activation.
Other pro-inflammatory cytokines such as interferon
gamma and tumour necrosis factor are also inhibited.
This multiplicity of immunosuppressive actions is not
fully replicated by other immunosuppressants.
However, there are concerns about the long-term side
effects of steroids.These include hyperglycaemia, dys-
lipidaemia, hypertension, truncal obesity, cushigoid
features, osteoporosis, aseptic bone necrosis, growth
disturbances in children and cataracts. The first four
factors may contribute to cardiovascular disease, a
leading cause of mortality and morbidity in transplant
patients (2).The cost of steroid-related side effects in
the US is estimated at $5,300 per patient (3).
This review will examine the attempts at steroid with-
drawal or steroid avoidance in renal transplant patients.
Concomitant maintenance immunosuppressants may
include calcineurin inhibitors (cyclosporine, tacrolimus),
antimetabolites (azathioprine, mycophenolate mofetil)
or sirolimus, which inhibits the mammalian target of
rapamycin (mTOR). During the initial, high-risk post-
transplant period, patients may also receive induction
therapy with OKT3 (an anti-CD3 monoclonal anti-
body), antithymocyte (ATG) or antilymphocyte (ALG)
globulins, or the IL2-receptor antagonists, basiliximab
or daclizumab.
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ABSTRACT: Steroids remain an important component of maintenance immuno-
suppression after renal transplantation. Their anti-inflammatory action is partly due to
the sequestration of CD4+ lymphocytes in the reticuloendothelial system. Steroids 
bind to intracellular receptors and the resulting steroid-receptor complex alters the
transcription of cytokines by binding to glucocorticoid response elements on DNA.
Transcription factors whose actions are altered by glucocorticoids include activating
protein-1 (AP-1) and nuclear factor-κB (NF-κB). The main cytokines whose production
by antigen-presenting cells is inhibited by steroids are interleukin-1 (IL-1), required for
helper T-cell activation, and IL-6, required for B-cell activation. Other pro-inflammatory
cytokines such as interferon gamma and tumour necrosis factor are also inhibited. This
multiplicity of immunosuppressive actions is not fully replicated by other immuno-
suppressants. However, there are concerns about the long-term side effects of steroids.
This review will examine the attempts at steroid withdrawal or steroid avoidance in
renal transplant patients. (JUMMEC 2006; 9(1): 2-6)
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Cyclosporine/azathioprine-based regimes
Cyclosporine gained widespread usage in renal trans-
plantation after it was shown to improve short term
graft survival compared to azathioprine (4,5,6). Steroid
withdrawal in the early (6-12 days) post-transplant
period was abandoned after it was found to increase
the rate of acute rejection (AR) (7). A meta-analysis 
of randomized controlled trials (RCT’s) of late steroid
withdrawal with this regime examined nine studies
with a total of 1,461 patients (8).The authors found a
14 per cent increase in AR and a 40% increase in graft
failure in the steroid withdrawal group. Steroid
withdrawal from patients with stable graft function at
1-6 years post-transplant (9). While there were no
documented AR episodes, serum creatinine at 1-year
post-withdrawal was significantly higher than in the
control steroid maintenance group. In the largest RCT,
worse 5-year graft survival in the steroid withdrawal
group was found, although this effect was not detected
on shorter follow-up (10). These two studies suggest
that apart from precipitating AR, steroid withdrawal
may also impair graft function, possibly by increasing
chronic rejection.The study (10) also emphasizes the
importance of long-term follow-up in these studies.
Because of these results, enthusiasm for steroid
withdrawal in patients on this regime has waned.
However, a recent trial studied the possibility of
steroid withdrawal with the addition of an anti-IL2
receptor antibody. One hundred fifty-seven patients
on cyclosporine and azathioprine were randomized to
receive induction with basiliximab or placebo. Steroids
were withdrawn five months post-transplant. Patients
in the basiliximab group had higher success in steroid
withdrawal, fewer AR’s (25.3% at 1 year) and fewer
graft losses (11).
Cyclosporine/mycophenolate mofetil-based
regimes
Mycophenolate mofetil (MMF) is an antimetabolite
which is superior to azathioprine in preventing AR
(12,13,14). Two major studies have looked at steroid
withdrawal in cyclosporine/MMF-based regimes. The
European trial (15) randomized 500 patients to
standard therapy or to steroid withdrawal after 12
weeks of half-dose prednisolone (low/stop group).
They found a higher AR rate at 12 months follow-up
in the low/stop group. Interestingly, there was no
difference between the groups among patients who
received induction therapy with OKT3 or antithymocyte
globulin. The US trial (16) recruited primary transplant
patients with no early AR and randomized them to
standard therapy or steroid withdrawal at three months
post-transplant. The study was terminated prematurely
when the steroid withdrawal group was found to 
have a much higher 1-year AR rate (30.8% vs 9.8%).
This difference was especially pronounced among the
African-American subjects. However, several recent
smaller RCTs have found no increase in AR after
steroid withdrawal (17,18,19).
Tacrolimus-based regimes
Tacrolimus is a calcineurin inhibitor which is superior
to cyclosporine in preventing AR (20,21,22) and
preserving graft function (23). There have been no
large RCTs of steroid withdrawal in patients on
tacrolimus-based regime. A retrospective analysis by
the Pittsburgh group of 795 patients on tacrolimus and
azathioprine or MMF found better graft survival in
patients in whom steroids were withdrawn (24).
However, there may be bias as these patients had
lower immunologic risks compared to those in whom
steroids were continued. A small RCT (25) involving
patients with low immunologic risks found no AR 
and 100 per cent graft survival in both steroid with-
drawal and maintenance group at 24-months’ follow-
up. However, four out of 48 patients developed rising
creatinine after steroid withdrawal, which recovered
after steroids were restarted.
Steroid sparing and avoidance protocols
A significant disadvantage of late steroid withdrawal is
that some steroid side effects, such as osteopaenia,
have their greatest effects during the early post-
transplant period, when high doses of steroids are
used. In addition, steroids may affect the development
of tolerance by inhibiting T-cell apoptosis (26). The
development of powerful induction immunosuppressive
agents has stimulated interest in the use of steroids
for only a limited period (i.e., a few days) or not at all.
Since the mid-nineties, a Danish centre has been using
a steroid-free protocol consisting of ATG for ten days
together with maintenance cyclosporine and MMF.
A review of 100 consecutive transplant recipients
showed a 1- and 4-year graft survival of 97% and 82%
respectively (27). There were only 13 episodes of AR,
mostly in the first three months, and all were suc-
cessfully reversed.A steroid-free regime is also possible
with Campath 1H, a lymphocyte-depleting, humanized
anti-CD52 monoclonal antibody. With two doses of
Campath 1H and low dose maintenance cyclosporine,
the Cambridge group was able to achieve graft
survival of 29/31 at a mean follow-up of 21 months,
with six episodes of AR (28).
Several studies have looked at regimes with anti-IL2
receptor antibody induction. With tacrolimus/MMF/
anti-IL2 receptor antibody immunosuppression, steroid-
free patients had a higher AR rate at six months post-
transplant, but the difference disappeared by 12
months. However, it is unclear whether the patients
4JUMMEC 2006: 9(1)
were randomized, and the mean follow-up period was
short (29).
A case series of patients receiving daclizumab induction
and maintained on cyclosporine and MMF was published
(30).The 1-year graft survival was 89 per cent with an
AR rate of 25 per cent, most of which were steroid-
responsive and the majority of which occurred in the
first month. However, by the end of the first year, a
third of the patients required maintenance steroids.
Further follow-up at three years post-transplant
showed good graft survival and graft function, and few
late rejections (31). A prospective RCT is in progress
comparing daclizumab induction and two days of
steroids with no daclizumab and 16 weeks of steroids.
Maintenace immunosuppression is with tacrolimus and
MMF. An interim analysis at a mean follow-up of 
11 months found no difference in AR rates between
the two groups (32).
Initial experience with basiliximab has been similarly
positive. A comparative study was done on a 4-day
steroid regime with steroid maintenance, with con-
comitant cyclosporine, MMF and basiliximab induction
(33). At six months’ follow-up, there was no difference 
in AR rate and serum creatinine between the two 
groups. A randomized study of 27 patients receiving
basiliximab/cyclosporine/MMF to maintenance steroids
or no steroids was carried out (34). The no steroids
group also received two extra doses of basiliximab at 
60 and 64 days post-transplant. There were no differ-
ences in AR and creatinine clearance after follow-up for
one year.
Sirolimus-based regimes
Sirolimus is a relatively new immunosuppressant with
a unique target (mTOR).There has not yet been RCTs
of steroid withdrawal using a sirolimus-based regime.
In an uncontrolled observational study, 75.4 per cent
of 156 patients on cyclosporine and sirolimus had
their steroids successfully withdrawn at one week to
two years post-transplant.At three years, the AR rate
was 6.4 per cent, the chronic rejection rate was 5.1
per cent and graft loss occurred in 7.7 per cent (35).
Metabolic benefits of steroid withdrawal
The main reason for steroid withdrawal is the
purported metabolic benefits. This assumption was
recently challenged by the findings of a retrospective
review (36). After a mean follow-up of 7.6 years, the
authors found no further metabolic benefits of
prednisolone reduction to below 10 mg every other
day. In addition, most of the early metabolic benefits of
steroid withdrawal were not sustained over longer
periods.
Identifying patients suitable for steroid with-
drawal/avoidance
The RCTs of steroid withdrawal cannot give us clear-
cut answers as to who can undergo steroid with-
drawal or be started on a steroid-free protocol. The
studies vary greatly in the patients’ characteristic, con-
comitant immunosuppression, timing and rate of
steroid withdrawal, duration of follow-up and study
end-points.Thus, the consideration of the risk:benefit
ratio should be individualized, based on the patients’
immunologic profile, transplant history and concomitant
medications, the severity of steroid-related side
effects, coexisting cardiovascular risk factors, and the
opportunity for a retransplant should the current graft
fail.
Thus, prime candidates for steroid withdrawal or
avoidance would be a non-sensitised recipient of a
well-matched graft from a living donor, without
delayed graft function or acute rejections, and who has
good, stable graft function. Steroid withdrawal or
avoidance should also be considered in patients who
already suffer from significant steroid-related side
effects (such as osteopaenia, or growth retardation in
children) or who have significant coexisting cardio-
vascular risk factors, especially diabetes mellitus,
dyslipidaemias, hypertension or a strong family history
of cardiovascular disease. Few patients are likely to
meet all these criteria, so the eventual decision should
be made after careful consideration by the clinician
and the patient.
Conclusion
In conclusion, newer, more powerful immuno-
suppressants have reduced the risk of steroid with-
drawal or avoidance. Many of the studies on these
agents are small, short and have not been published in
peer-reviewed journals. In addition, the metabolic
benefits of steroid withdrawal may not be sustained
nor superior to low dose maintenance steroids.
Therefore, the overall risk:benefit ratio should be
individualized for each patient.
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7CYTOPROTECTIVE EFFECTS OF HONEY IN
COMBINATION WITH AQUEOUS AND ETHANOL
EXTRACTS FROM CHROMOLAENA ODORATA L.
(EUPATORIUM ODORATUM L.) IN RATS
Nur Jannah MH, Mahmood AA, Sidik K and Salmah I
Department of Molecular Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
ABSTRACT: Six groups of adult Sprague-Dawley rats were orally administered with 
a variety of treatments to elucidate their cytoprotective effects. Absolute ethanol
combined with HCl was used to induce gastric lesions in rats. Aqueous and ethanol
extracts of Chromolaena odorata, a famous folk herb for treating skin wounds were
evaluated to determine their protective effect on gastric mucosa. In this study, aqueous
extract and ethanol extract of C. odorata were combined with honey. In addition,
honey alone and honey combined with cimetidine were also evaluated. Rat stomachs
were examined grossly and histologically. Results were expressed as inhibition per-
centage. The honey and aqueous extract combination showed the highest inhibition
percentage (72.67%) followed by honey and ethanol extract (58.92%), honey and
cimetidine (56.55%) and the lowest was honey alone (46.74%). However, there were 
no significant differences between the effects of aqueous and ethanol extracts of 
C. odorata and honey in promoting cytoprotective effects and this may be due to the
small sample size. Nevertheless, these results suggest that C. odorata and honey may
be beneficial in treating induced gastric mucosal injury. (JUMMEC 2006; 9(1): 7-13)
KEYWORDS: Honey, cimetidine, ulcer, Chromolaena odorata, rats 
Introduction
The definition of cytoprotective effects could be
interpreted as the capability of a compound to
prevent the formation of gastric mucosa necrosis
produced by a variety of necrotizing agents, without
reducing acid secretion. The exact mechanism of
gastric cytoprotective effects in maintaining the
cellular integrity of the gastric mucosa that are
subjected to strong irritants is unknown (1).
In humans, the gastric mucosa is often bombarded
with aggressive exogenous and endogenous luminal
agents.Therefore, the body has its own cytoprotective
properties to retain mucosal layer integrity and
reduce the frequency of developing erosions, ulcers,
and hemorrhages (2).
For example, glutathione, which is abundant in the
stomach, was demonstrated to be protective against
ethanol-induced gastric mucosal damage by scaven-
ging free radicals (3). Besides glutathione, pro-
staglandin activity (1) and activation of Protease-
activated receptor-2 (PAR-2) also exert a cyto-
protective effect (4).
In a healthy human stomach, an efficient equilibrium
exists between the potential for gastric acid and
pepsin to damage gastric mucosal cells and the ability
of these gastric cells to protect themselves from 
injury (5). There are many reasons which lead to
gastric mucosal injury that consequently caused the
exposure of hydrochloric acids and pepsin to the
underlying epithelial cells. It was suggested that one
reason is that reactive oxygen species (ROS) can
chemically induce gastric mucosal injury. Further-
more, it was investigated that ROS may cause DNA
fragmentation (5).
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A report suggested that natural honey is able to
protect the rat stomach and also able to accelerate
healing against acute ethanol- and indomethacin-
gastric lesions (6). Another study also explained 
the effects of honey in gastroprotective activity.
The report mentioned that the mechanism of gastro-
protective properties in honey against ethanol-
induced gastric haemorrhagic lesions is mediated
through sulfhydryl (SH)-sensitive processes. In refer-
ring to the previous statement, it was suggested that
honey has many similar features to sucralfate, which is
a locally acting anti-ulcer drug. Honey and sucralfate
have both been shown to deliver protection against
ethanol-induced gastric haemorrhagic lesions by pre-
venting depletion of endogenous non-protein SH
mainly in the form of glutathione (GSH). Consequently
both honey and sucralfate have the ability to inhibit
vascular permeability changes and vascular damage
which are induced by ethanol (7).
Besides that, the constituents of catalase in honey are
able to promote protection against the toxic effects of
oxygen-derived free radicals (ODFRs) and abolish the
increment of endothelial cell permeability (7).
Chromolaena odorata (L) King and Robinson (formerly
Eupatorium odoratum), belongs to the family Astera-
ceae and is a native plant of South and Central
America.This species has, however, successfully spread
to other warm and humid tropical regions such as
South Africa, Vietnam, India, Indonesia, Malaysia, Sri
Lanka and the Philippines (8,9).
It is a herbaceous perennial, which grows into a big
bushy herb or subshrub and can reach up to the height
of three meters in open area (8,10,11). C. odorata is
believed to be a poisonous plant with exceptionally
high levels of nitrate, which is five to six times above
the toxic level especially in the leaves and young
shoots (12). However, C. odorata is a famous herbal
remedy in treating wounds. In Vietnam, the fresh 
leaves and extracts of the plant have been long used 
in treating burns, soft tissues and skin infections (13).
Even though there are not many studies done to
evaluate the use of C. odorata extracts in preventing
ulcer, there are claims that C. odorata can be used as
treatment for abdominal disorders. A study also
showed that methanol extract of the leaves of 
C. odorata possess anti-inflammatory, antipyretic and
antispastimodic properties.The study also established
that the extract attributed to antimotility and anti-
diarrheal effects (14).
The leaves of C. odorata have the maximum amount 
of allelochemicals (15). A study in Vietnam showed
that the aqueous extract of the leaf consisted of
flavonoids (salvigenin, sakuranetin, isosakuranetin,
kaempferide, betulenol, 2-5-7-3 tetra-O-methyl quer-
cetagetin, tamarixetin, and two chalcones, odoratin,
and its alcoholic compound), essential oils (geyren,
bornyl acetate, beta eubeden), saponin triterpenoids,
tannins, organic acids, and numerous trace substances
(16).
Another study showed that the crude ethanol extract
of C. odorata contains phenolic acids (protocatechuic,
p-hydroxybenzoic, p-coumaric, ferulic and vanilic
acids) and complex mixtures of lipophilic flavonoid
aglycones (flavanones, flavonols, flavones and chal-
cones) (17).
In this study, a comparison was made between
aqueous and ethanol extracts of C. odorata mixed 
with honey to determine which method of extraction
resulted in better cytoprotective effect to the gastric
mucosa. Cimetidine, a H2-receptor antagonist was also
mixed with honey and evaluated for its cytoprotective
effect.
Materials and Methods
Honey
The honey used in this study was pure, unprocessed,
unboiled and commercialized, purchased from the
Faculty of Agriculture, University Putra Malaysia,
Serdang, Selangor, Malaysia. The honey was filtered
before use.
C. odorata
Leaves were separated from the stalk and were dried
in an oven at 50°C for 5-7 days or until the leaves
were fully dried. Then the leaves were ground. The
aqueous extract of C. odorata was prepared by placing
ground leaves in a conical flask. Sterile water was
added such that for every 1 g of ground leaves was 20
ml of sterile water (1:20).Then the flask containing the
ingredients was left and the contents macerated for
three hours on a hot plate. The ethanol extract of 
C. odorata was prepared by placing the ground leaves
in a conical flask and 96% denatured ethanol was
added in the proportion of 1 g of ground leaves to 
20 ml of 96% denatured ethanol (1:20).The flask con-
taining the ingredients was then left for maceration 
for approximately 5-7 days at room temperature.
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Next, the crude extracts from aqueous and ethanol
extractions were filtered with a filter funnel to
remove the filtrate. After that, the filtered extracts
were concentrated with the aid of a rotary evaporator
at 60°C. Finally, the concentrated extracts were
freeze-dried to produce a powdery form of the
extracts, which were stored at -20°C until use.
Preparation of honey in combination with
C. odorata extracts and cimetidine
Honey was combined with aqueous and ethanolic C.
odorata extracts respectively at (10% w/w) (5 ml kg-1).
Cimetidine was also combined with honey at 10 mg/
1 ml (5 ml kg-1).
Animals
The rats were caged individually in a cylindrical stain-
less steel cage to avoid coprogaphy. The rats were
deprived of food but allowed free access to tap water
for 48 hours prior to the experiments. Water was
withheld about 18 hours before the experiments. Six
rats were assigned to each group and labeled as
follows, normal (Group 1); ulcer control (Group 2);
pre-treatment with honey alone (Group 3); pre-
treatment with honey combined with aqueous C.
odorata extracts (Group 4); pre-treatment with honey
combined with ethanolic C. odorata extracts (Group
5); and pre-treatment with honey combined with
cimetidine (Group 6). Thirty minutes later, 1 ml of
absolute ethanol combined with HCI (0.6 N HCl
mixed with equal volume of absolute alcohol) was
orally administered to each rat in Group 2, Group 3,
Group 4, Group 5 and Group 6 to induce gastric
ulceration. Then, 30 minutes later, all the rats were
sacrificed by administrating an overdose of diethyl
ether then their stomachs were removed and main-
tained in 10% formalin for further gross and
microscopic examination.
Gross and microscopic examination 
Each stomach was cut along the greater curvature.The
mucosal lesions were traced under the dissecting
microscope (x20) with the aid of square-grid eyepiece
(1 mm square).The ulcer index (UI) was determined
as the sum of gastric lesions for each stomach and the
inhibition percentage was expressed as a percentage
of the control by the following formula, as earlier
described (18):
Inhibition percentage (%) 
= [ (UIulcer control –  UItreated) / UIulcer control ] x 100
The stomachs were then trimmed and fixed. Next,
the tissues were processed, embedded in paraffin,
and subsequently sectioned.The sections were stained
with haematoxylin and eosin (H & E) and examined
under light microscope at x10 and x40 magnification.
Results 
Group 1 (Normal) – Rats administered with
distilled water
Rats in this group were administered with distilled
water and served as the normal control group.There
were no thick black or red lines at the outer stomachs,
which were observed before the stomachs were cut
opened. Gross examination showed no haemorrhaging
and the mucosal rugae was in normal condition. The
histology results showed no red blood cells and intact
mucosal cells without gastric edema. The submucosa
layer appeared to be in normal condition.
Group 2 (Ulcer control) – Gastric lesions
produced by absolute ethanol combined
with HCl
Oral administration of 1 ml absolute ethanol combined
with HCl (mixed equal volume of each) to the rats
produced extensive necrosis of the gastric mucosa.
Thick black or red lines were visible outside the
stomachs, which indicated severe gastric damage.
Gross examination showed a large amount of
haemorrhagic lesions confined mostly in the gastric
corpus, which is the secreting region of the stomach.
Histologically, necrosis involved about two-third of the
mucosa layer and exfoliation of the mucosal cells was
detected. Meanwhile, red blood cells were present in
the gastric mucosa and edematous submucosa was
discovered as well. Inflammatory exudates were also
found around the mucosal layer.
Group 3 – Effects of honey alone on gastric
lesions produced by absolute ethanol com-
bined with HCl
Pre-treatment with honey alone before the induction
of gastric lesions by absolute ethanol combined with
HCl showed modest cytoprotective effect to the gastric
mucosa.About half of the stomach showed haemorr-
hagic condition. Honey inhibition of gastric lesions
produced by absolute ethanol combined with HCl was
46.74% (Table 1). Histological examination showed 
the presence of red blood cells and moderate exfolia-
tion of mucosal epithelial cells. However, the mucosa
10
JUMMEC 2006: 9(1)
appeared to be eroded with the presence of exudates.
Neutrophils were found around blood vessels of the
submucosa.
Group 4 – Effects of honey combined with
aqueous extract of C. odorata on gastric
lesions produced by absolute ethanol com-
bined with HCl
Pre-treatment with honey and aqueous extract of 
C.odorata significantly prevented the formation of gastric
lesions produced by absolute ethanol combined with
HCl at an inhibition percentage of 72.67%. Gross
examination showed mild haemorrhage lesions with
the ulcer index of 326.50 ± 31.93 (Table 1). Histo-
logical examination showed intact mucosa layers with
mild exfoliation of endothelial cells and a slight ede-
matous submucosa was detected. However, the
mucosal layer showed moderate haemorrhagic con-
dition with the presence of red blood cells.
Group 5 – Effects of honey combined with
ethanol extract of C. odorata on gastric
lesions produced by absolute ethanol com-
bined with HCl
Pre-treatment with honey combined with ethanol
extract of C. odorata, grossly showed reduction of
58.92% gastric lesions induced by absolute ethanol
combined with HCl. This pre-treatment indicated
reliable cytoprotective effects. Histological examina-
tion showed fragile and eroded mucosa layers with
moderate exfoliation of endothelial cells. In addition,
edematous submucosa and red blood cells was
detected.
Group 6 – Effect of honey combined with
cimetidine on gastric lesions produced by
absolute ethanol combined with HCl
Oral administration of cimetidine combined with
honey reduced the formation of gastric lesions that
was produced by absolute ethanol combined with HCl
at inhibition percentage of 56.55%. This treatment
showed cytoprotective effects. Histological exami-
nation showed intact mucosa layers with barely any
exfoliation of endothelial cells. However, moderate
edematous submucosa was detected with the appear-
ance of marginated neutrophil around blood vessels and
the superficial region of mucosal layer showed broad
haemorrhagic condition.
Discussion
By calculating the inhibition percentage of gastric
lesions, all the treatments were compared to ulcer
control to measure the percentage that each treat-
ment inhibited gastric lesions. All four treatments
showed statistical significance when compared to
ulcer control. Rats pre-treated with aqueous extract 
in combination with honey showed the highest
inhibition percentage (72.67%) followed by rats pre-
treated with alcoholic extract in combination with
honey (58.92%), rats pre-treated with cimetidine in
Group Treatment No. of Ratio of Treatment Dose Ulcer Index Inhibition
Rats to Honey (Mean ± S.E.M) (%)
1 Normal saline 6 – 5 ml kg-1 9.17 ± 3.11a –
(normal)
2 Abs. ethanol + HCl 6 – 5 ml kg-1 1194.83 ± 121.02b –
(ulcer control)
3 Honey alone 6 – 5 ml kg-1 636.33 ± 26.72c 46.74
4 Aqueous extract 6 10% w/w 5 ml kg-1 326.50 ± 31.93d 72.67
C. odorata + Honey
5 EtOH. extract 6 10% w/w 5 ml kg-1 490.83 ± 52.21cde 58.92
C. odorata + Honey
6 Cimetidine + Honey 6 10 mg/1 ml 5 ml kg-1 519.17 ± 12.23e 56.55
Table 1. Tabulated results of gross examination of all oral treatment
All values are expressed as means and standard error. Mean with different superscripts are significantly different at (P < 0.05).
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combination with honey (56.55%) and the lowest was
for rats pre-treated with honey alone (46.74%).
In this study, absolute ethanol combined with HCl was
used as necrotizing agents to induce ulcer in rats.
Ethanol and HCl-induced gastric ulcers are commonly
used for evaluation of anti-ulcer activity (19). Absolute
ethanol and HCl rapidly penetrates the gastric mucosa
(20,21), which explains why 30 minutes was sufficient
for developing gastric lesions in rats. In this study, oral
administration of absolute ethanol combined with 
HCl produced extensive exfoliation of gastric mucosa
cells which caused bleeding and inflammatory exuda-
tion. Ethanol causes haemorrhage lesions by inducing
endothelin-1 and constricts gastric vasculature, there-
by causing stasis in blood flow (22).
Ethanol also incites vascular damage and alters mucosal
microvascular permeability (7). It was suggested that
depletion of non-protein sulfhydryl concentration and
modulation of nitric oxide system are few of the factors
contributing to ethanol-induced gastric lesions (6).
Furthermore, reduction in glutathione level and pro-
duction of oxygen-derived free radicals may contri-
bute to ethanol-induced mucosal damage (7).
Subsequently, these factors stated above lead to the
release of vasoactive products from mast cells (e.g.
histamine), macrophages, polymorphonuclear leuko-
cytes and other blood cells,which may lead to vascular
injury, necrosis, and ulcer formation (20). Other roles
of ethanol in generating ulcer also involve disturb-
ances in gastric secretion, gastric mucus reduction
(19) and causing submucosal edema (1).
In this study, in addition to evaluating the cyto-
protective effects of honey alone, the effect of honey
when combined with plant extracts and cimetidine
were also evaluated. It was suggested that honey acted 
as vehicle, whereby honey attributed to the cyto-
protective effects of C. odorata extracts. The same
study also claimed that honey when combined with
plant extracts, was more effective in its cytoprotective
effect than the plant extracts alone (23). In addition,
another reason for combining honey at 10% w/w with
C. odorata extracts was because honey may help to
reduce the toxic effect of the plant extract.
Honey alone showed moderate cytoprotective effects
in protecting gastric mucosa against ethanol and HCl.
The cytoprotection mode of honey may mainly involve
reduction in vascular permeability (7) and an increase
in gastric mucosal blood flow (6). Inflammatory exu-
dates levels were found to have decreased (24). In
addition, the ability of honey to absorb edema,
promote epithelialisation and improve the state of
nutrition also contribute to the healing process (6,24).
Furthermore, honey also possesses antioxidant
properties that abolish the increment of endothelial
cell permeability (7). This may be the key factor of
honey in preventing extensive exfoliation of mucosal
cells induced by ethanol and HCl.
C. odorata is a popular herbal remedy in treating
wounds, burns and skin infection (13). Although 
C. odorata has not been well established in promoting
cytoprotection toward gastric mucosa,many properties
of C. odorata in wound healing can be applied in eluci-
dating the mode of protection produced by C. odorata
in this study.
Polysaccharides are general constituents of Astera-
ceae family, which holds many therapeutic properties.
Alginic acid (heterogeneous polysaccharides) was
suggested to form gel layer and acts as barrier against
excessive pH changes and thus protects the gastric
mucosa (25). It is speculated that polysaccharide con-
stituents contribute to the production of cytopro-
tective effects in C. odorata.
The aqueous extracts of C. odorata in this study
significantly inhibited the action of ethanol in
combination with HCl in inducing ulcer. The cyto-
protective effect is statistically significant when com-
pared to honey alone, which showed that the cyto-
protective effects of aqueous extracts of C. odorata
combined with honey was not merely due to the
honey only. It was observed that exfoliation of gastric
mucosa cells was mild and only occurred at the super-
ficial layer. This may be due to the powerful anti-
oxidant (17) and anti-inflammatory (14) properties of 
C. odorata, which must have prevented the decrease in
mucosal cells and vascular permeability induced by
ethanol and HCl.
The capacity of C. odorata to stimulate the expression
of many essential proteins (13) such as increasing
endogenous prostaglandin may also contribute to
decrease in vascular permeability (26). Furthermore,
the extracts of C. odorata are known to increase proli-
feration of epithelial cells (17) and may be involved in
the healing process of gastric mucosa.The presence of
red blood cells was detected and this may be due to
enhancement of haemostasis by C. odorata extract to
stop bleeding (16).
Compared to the aqueous extract of C. odorata, the
ethanol extract of C. odorata only showed modest
cytoprotective effects in preventing gastric damage
induced by absolute ethanol and HCl. Even though
exfoliations of gastric mucosal cells were moderate,
inflammatory exudates were found particularly in the
12
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mucosal and submucosa layers, which may explain the
fragile and eroded mucosa layers. This may due to a
slight increase of vascular and mucosal cells per-
meability (27). Furthermore, red blood cells were also
detected in the mucosal layers and may also be due to
the same reason (20).
Even though the ethanolic method of extraction was
also used to extract C. odorata in this study, heating 
the plant in water has actually been the traditional
Vietnamese method of preparing C. odorata extracts.
Furthermore, chromatography evaluation indicated
that the compounds found in C. odorata extracts 
such as flavonoids and other phenolic compounds are
soluble in hot water. Therefore, it was thought that
aqueous extraction method was the best way to
obtain the constituents of C. odorata (16), and this may
be the reason why the aqueous extract of C. odorata
was more effective in inhibiting gastric lesions induced
by ethanol and HCl compared to the ethanolic extract
of C. odorata in this study. However, the difference
between aqueous extract of C. odorata and ethanolic
extracts of C. odorata in generating cytoprotective
effects was not statistically significant. This was pos-
sibly due to the small number of rats used in the study.
Furthermore, pre-treatment with ethanolic extract of
C. odorata combined with honey was not statistically
significant compared to pre-treatment with honey
alone (Group 3) and neither was it significant com-
pared to pre-treated with cimetidine combined with
honey (Group 6).
Histological examination of the group that was pre-
treated with cimetidine combined with honey showed
a rather intact mucosal layer even though a broad
superficial region of mucosa layer appeared haemorr-
hagic. Cimetidine is well known for its effectiveness in
reducing gastric acidity (28) and this may be the
reason behind the intact mucosa layer in this group.
A study suggested that cimetidine possesses direct
cytoprotective effects on the gastric mucosa (29).
However, the dose of cimetidine used in that study
was higher (300 mg kg-1) compared to the dose used
in the present study, 50 mg kg-1. This may explain the
haemorrhages at the superficial region of mucosa layer
and also the presence of edematous submucosa (27).
The pre-treatment of cimetidine combined with
honey was statistically significant compared to pre-
treatment of honey alone.
Conclusion
In conclusion, honey alone, aqueous and ethanol extracts
of C. odorata and cimetidine possess cytoprotective
properties. Through histological examination, it was
speculated that the cytoprotective effects observed 
in this study include decreased exfoliation of mucosal
cells, reduced inflammatory exudates, minimizing
mucosal cells and vascular permeability chances.
Furthermore, in this study, there was no statistical
significance between aqueous and ethanolic extracts
of C. odorata in promoting cytoprotective effects.
Nevertheless, both extracts of C. odorata were able 
to deliver satisfying cytoprotective effects in reducing
gastric mucosal lesions induced by absolute ethanol
combined with HCl.
Further investigation of C. odorata in inducing cyto-
protectiveness needs to be carried out because it
might be beneficial in treating a variety of diseases that
are related to gastric mucosal injury.
However, for human consumption, further pharmaco-
logical tests need to be conducted to determine
appropriate doses for humans and to uncover any
adverse effects which may arise from administration of
C. odorata.
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PSEUDOMONAS AERUGINOSA: EPIDEMIOLOGY OF
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Nadeem SR, Rina K, Hamimah H and Savithri DP
Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
ABSTRACT: A cross-sectional study of 109 patients with Pseudomonas aeruginosa
bacteremia from the University of Malaya Medical Centre (UMMC) in the years 2000
and 2001 was conducted to describe epidemiological features, underlying diseases,
possible source of infection, early mortality among patients as well as the antibiotic
susceptibility pattern of patients’ isolates. Further analysis of the 87 patient records
that were available revealed that the mean age was 48.5 years (SD ± 25.1). Fifty-two 
per cent of cases were male and 48% female. Seventy-nine per cent of infections were
nosocomially acquired, 33% of bacteremias were polymicrobial, 47% of patients had a
continuous bladder drainage catheter (CBD) in situ, 33% had a central venous catheter
(CVL) present at the time of bacteremia and 30% were ventilated. Sixty-eight per cent
of patients had an underlying immunosuppressed state and 26% had undergone
surgery involving general anesthesia in the week prior to isolating P. aeruginosa.
Among the 23 patients with early mortality, 61% were on inappropriate antimicrobials.
Most of the patients’ isolates were sensitive to imipenem (86%), ciprofloxacin (81%),
ceftazidime (79%), gentamicin (78%) and cefoperazone (77%). Among the community
acquired strains, however, there was 100% sensitivity to imipenem, ceftazidime, cefo-
perazone and ciprofloxacin. (JUMMEC 2006; 9(1): 14-19)
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Introduction
Pseudomonas aeruginosa bacteremia has become an
important cause of mortality and morbidity over the
past few decades. Despite the advent of new anti-
microbials and improved health standards, mortality
ranges from 18-61% (1) which some studies have 
found is higher than mortality from other gram-
negative bacteremias (2). This increased mortality may
be reflective of more severe underlying illness or could
be related to the greater inherent virulence of the orga-
nism (3), or the fact that the organism may develop
resistance while the patient is on treatment (4).
P. aeruginosa, a gram-negative bacillus, is generally recog-
nized as an opportunistic and nosocomial pathogen
and rarely causes disease in healthy persons (2,3).
It is recovered infrequently from the endogenous
microbial flora of healthy individuals (2). It is a com-
mon pathogen, however, in patients hospitalized for
more than a week and predisposing conditions to
developing bacteremia include having an underlying
immunosuppressed state, admission to intensive care
units, respiratory therapy, surgical procedures, the
presence of various catheters and antimicrobial
therapy (2,3,5). Community-acquired cases have also
increased and this may be related in part to the
prevalence of HIV infection and reports that in HIV
infected patients, P. aeruginosa bacteremia may be
community-acquired (6).
There have not been any epidemiological studies on 
P. aeruginosa bacteremia in Malaysia.The objectives of
this study were to describe the epidemiologic features,
underlying diseases, possible source of infection,
percentage of early mortality and the antimicrobial
JUMMEC 2006: 9(1)
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susceptibility pattern of isolates in patients with P.
aeruginosa bacteremia at a tertiary level teaching
hospital in Malaysia in the years 2000 and 2001.
Material and Methods
Patients
All 109 patients with P. aeruginosa bacteremia in the
years 2000 and 2001 were identified from the com-
puterized microbiology records of the Microbiology
laboratory of the University of Malaya Medical Centre
(UMMC), an 844-bed major teaching hospital in Kuala
Lumpur, Malaysia. There were 45 cases in the year
2000 and 64 cases in the year 2001. However, only 
87 patient records were available for further analysis.
Inclusion criteria for P. aeruginosa bacteremia was at
least one positive blood culture from a patient with
suspected bacteremia. Cases with polymicrobial bac-
teremia involving P. aeruginosa were also included in
this study. The patients’ demographic information as
well as information regarding therapy with steroids,
cytotoxic drugs, presence of hematological or other
malignancies, other immunosuppressed states like
burns and post-splenectomy, diabetes mellitus, central
venous lines (CVL), continuous bladder drainage
catheter (CBD) and mechanical ventilation was
recorded. Patients who had undergone surgery in the
week prior to the isolation of P. aeruginosa from the
blood were also identified.
Microbiology 
The microbiology data collected included the anti-
microbial sensitivity pattern of all 109 bacteremic 
P. aeruginosa isolates as well as the types of organisms
isolated in the polymicrobial cases. If the organism was
isolated from another site of the body within a week
prior to the positive blood culture, this was also
recorded.
Blood cultures were processed by the Bactec 9240
system (Becton-Dickinson Microbiology System,
USA). P. aeruginosa was identified by conventional
bacteriological methods or by the API 20NE system
(bioMérieux, France). Antibiotic susceptibility testing
by disc diffusion was in accordance with the National
Committee for Clinical Laboratory Standards
(NCCLS) (7,8).
Definitions
Nosocomial infection was defined as a positive blood
culture taken 48 hours after admission with no
evidence of Pseudomonas aeruginosa infection at the
time of admission.The bacteremia was considered to
be community-acquired if P. aeruginosa was isolated
within 48 hours of hospital admission and the patient
had not been admitted in the previous two weeks (1).
Patients were classified as immunosuppressed if they
were on cytotoxics or steroids, had underlying malig-
nancy, diabetes, HIV infection, systemic lupus erythe-
matosus, burns, or had been splenectomized. Diabetes
as an underlying factor was also analyzed separately.
Polymicrobial bacteremia was defined as the isolation
of other organisms in addition to P. aeruginosa from
the blood culture. If a specimen from any site of the
body grew P. aeruginosa within a week prior to isola-
ting the organism from the blood, it was considered 
a possible portal of entry; otherwise, the source of
bacteremia was considered unknown. Early mortality
was defined as death occurring within 72 hours of
isolating the organism from a blood culture and
antimicrobial therapy at the time of bacteremia in
these cases was considered appropriate if the strain of
Pseudomonas aeruginosa isolated was sensitive to any
of the antimicrobials given to the patient and if the
patient received adequate dosage of that antibiotic for
at least 24 hours prior to death.
Results
Demography
Table 1 shows the characteristics of the study subjects.
The mean age of the 87 patients was 48.5 years (SD ±
25.1; range: 13 days old to 92 years). Fifty-two per cent
Table 1. Characteristics of study subjects
Risk factors No. of patients (%)
(Total patients n=87)
Age (Year)
0 – 12 11 (13%)
13 – 29 10 (11%)
30 – 49 17 (20%)
50 – 69 33 (38%)
> 70 16 (18%)
Sex
Male 45 (52%)
Female 42 (48%)
Ward type 
Intensive care units 20 (23%)
Surgical 22 (25%)
Hematological 19 (22%)
Adult medical 15 (17%)
General paediatric 5 (6%)
Gynaecology 4 (5%)
Renal 2 (2%)
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of patients were male and 48% were female. Twenty
patients (23%) had been in an ICU at the time of
bacteremia, 22 (25%) were from the surgical wards,
15 (17%) were from the adult medical ward, 5 (6%)
were from the general paediatric wards, 19 (22%)
from the haematology wards, 4 (5%) were from the
gynaecology ward, and two patients (2%) were from
the renal wards.
Underlying disease associated with P. aeru-
ginosa bacteremia 
Fifty-nine patients (68%) were classified as immuno-
suppressed at the time of bacteremia (Table 2).
Twenty patients (23%) had underlying haematological
malignancy, 22 (25%) had other non-haematological
malignancies, 11 (13%) were on steroids, three (3%)
had burns, three (3%) had systemic lupus erythe-
matosus, two (2%) had been splenectomized and two
(2%) had HIV infection. Twelve patients (14%) were
diabetic.
Forty-one patients (47%) had a CBD in situ, 29 (33%)
had a CVL present at the time of bacteremia and 26
patients (30%) were on ventilator. Twelve patients
(14%) had undergone surgery involving general
anesthesia in the week prior to isolating P. aeruginosa
from the blood. Six patients (7%) had a tracheostomy
and one patient had a ventriculo-peritoneal shunt.
Source of infection 
Among the 87 bacteremic cases, sixty-nine (79%) were
nosocomial in origin whilst 16 (18%) were community-
acquired (Table 2). In two patients (2%), the informa-
tion available was insufficient to determine a noso-
comial or community origin.Among the patients with
community-acquired bacteremia, nine (56%) had
underlying carcinoma, haematological malignancy, or
had undergone bone marrow transplant.The remain-
ing seven patients had the following underlying
conditions: polycystic kidneys and urinary tract
infection with P. aeruginosa, HIV infection, diabetes
with gangrene of the foot, liver cirrhosis, burns, upper
gastrointestinal tract bleeding with polymicrobial
bacteremia, and one was an infant with a prior history
of being admitted to the special care nursery a month
earlier.
The urinary tract was possibly the commonest
identified site of entry (11%); this was followed by 
the respiratory tract (10%) and intravenous catheters
(6%) (Table 2).Thirteen per cent of patients also had
various wound swabs and drainage fluids growing 
P. aeruginosa in the week prior to isolation of the
organism. However, it was not possible to determine
accurately where the swabs and fluids had been taken
from due to the retrospective nature of the study. In
62% of cases the site of entry was unknown.
Early mortality
Early mortality occurred in 26% (23/87 patients), and
the P. aeruginosa bacteremia is likely to have been a
contributing factor. Table 2 shows patient character-
istics and underlying conditions in relation to early
mortality.
Of the 23 patients with early mortality, 70% were
male, 70% had monomicrobial bacteremia, 61% had
nosocomial bacteremia, 61% were on inappropriate
antibiotics, 61% had an underlying immunosuppressed
state and 52% had a CBD catheter.
Microbiology
Twenty-nine cases (33%) were polymicrobial with various
other organisms isolated in addition to P. aeruginosa
(Table 3). Gram-negative bacilli and gram-positive
cocci were isolated from 14 and 9 specimens respec-
tively. Six specimens yielded both gram-negative bacilli
and gram-positive cocci in addition to P. aeruginosa.
The commonest organism isolated was Staphylococcus
aureus, followed by Enterococcus spp. More than half
(52%) of the polymicrobial bacteremia cases were
from intensive care unit (ICU).
Antimicrobial sensitivity of isolates
All isolates had been tested for sensitivity against
ceftazidime, cefoperazone, gentamicin, ciprofloxacin
and imipenem. The majority of isolates (86%) were
sensitive to imipenem, 81% were sensitive to cipro-
floxacin; this was followed by ceftazidime (79%),
gentamicin (78%) and cefoperazone (77%) (Table 4).
Among the community-acquired strains, however,
there was 100% sensitivity to imipenem, ceftazidime,
cefoperazone and ciprofloxacin.
There were three strains resistant to piperacillin but
sensitive to piperacillin/tazobactam, two strains were
sensitive to imipenem but resistant to meropenem and
another two were resistant to imipenem but sensitive
to meropenem.Among the aminoglycosides, there were
11 isolates resistant to gentamicin but sensitive to
amikacin, but none were sensitive to gentamicin and
resistant to amikacin. There were four multi-resistant
strains which were only sensitive to polymixin B. Two 
of these strains came from patients in the ICU, and 
one each from the adult surgical and medical wards.
JUMMEC 2006: 9(1)
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Table 2. Patient characteristics and underlying conditions in relation to early mortality
Patient characteristic/ No. of patients (%) No. of patients dying No. of patients dying in 72 hours/ 
underlying condition within 72 hours (%) total patients in the group
(Total patients n=87) (Total patients n=23) (% total in the group)
Age (Year)
0 – 12 11 (13%) 5 (22%) 5/11 (45%)
13 – 29 10 (11%) 2 (9%) 2/10 (20%)
30 – 49 17 (20%) 2 (9%) 2/17 (12%)
50 – 69 33 (38%) 10 (43%) 10/33 (30%)
> 70 16 (18%) 4 (17%) 4/16 (25%)
Sex
Male 45 (52%) 16 (70%) 16/45 (36%)
Female 42 (48%) 7 (30%) 7/42 (17%)
Admission to an intensive 20 (23%) 8 (35%) 8/20 (40%)
care unit
Immunosuppressed state 59 (68%) 14 (61%) 14/54 (24%)
All malignancies 42 (48%) 8 (35%) 8/42 (19%)
– Haematological malignancies 20 (23%) 7 (30%) 7/20 (35%)
– Other malignancies (bowel 22 (25%) 4 (17%) 4/22 (18%)
cancer, gynaecological, etc.)
Diabetic patient 12 (14%) 2 (9%) 2/12 (17%)
Presence of CBD 41(47%) 12 (52%) 12/41(29%)
Presence of CVL 29 (33%) 6 (26%) 6/29 (21%)
On ventilator 26 (30%) 8 (35%) 7/26 (27%)
Recent surgery 12 (14%) 2 (9%) 2/12 (17%)
Source of bacteremia
– Nosocomial 69 (79%) 16 (61%) 16/69 (23%)
– Community* 16 (22%) 7 (39%) 7/16 (45%)
Possible route of entry
Respiratory tract 9 (10%) 2 (9%) 2/9 (22%)
Urinary tract 10 (11%) 2 (9%) 2/10 (20%)
Central venous catheters 5 (6%) 1 (4%) 1/5 (20%)
Others (swabs/drainage fluids) 11 (13%) 2 (9%) 2/11 (18%)
Type of bacteremia
Monomicrobial 58 (67%) 16 (70%) 16/58 (28%)
Polymicrobial 29 (33%) 7 (30%) 7/29 (24%)
Treatment
Appropriate – 9 (39%) –
Inappropriate – 14 (61%) –
* Of the community-acquired cases, nine had underlying malignancies or had undergone bone marrow transplant.The remaining seven had
the following underlying conditions: polycystic kidneys with a urinary tract infection (P. aeruginosa), diabetes with gangrene of the foot,
HIV infection, liver cirrhosis, burns, upper gastrointestinal tract (GIT) bleeding with polymicrobial bacteremia, and a history of having 
being admitted to the special care nursery a month earlier.
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Discussion
The majority of patients with P. aeruginosa bacteremia
had an underlying immunosuppressed state or some
device present that predisposed them to the develop-
ment of infection, this being similar to findings in other
published reports (1,3). The patients were mainly
distributed among the intensive care units, surgical and
haematological wards, whereas a predominance of
patients from the general surgical and transplant
services were found (6).
Although most of the cases (79%) were nosocomial
infections, community-acquired cases were also seen
(18%) and these findings were similar to a recent study
(9). Research has shown that only 12% (1) of cases
were community-acquired whereas a rate of 40% was
reported (6).This was higher than their earlier study
of 17% and the increase in community-acquired cases
was partially attributed to the prevalence of HIV
infection as in seven out of 11 episodes of P. aeruginosa
bacteremia in these patients, the bacteremia was
community-acquired (6). In our study, we had only one
patient with underlying HIV infection among the
community-acquired cases but most patients had
some other underlying immunosuppressed state or
predisposing factor.
Early mortality in our study was seen in 26.3% of
patients. In a study of Pseudomonas septicemia in
cancer patients 33% of patients died in the first 
24 hours (10). In another study, 21 out of 23 patients
had cancer, and the median period of survival from the
positive blood culture was four days (11).
Polymicrobial bacteremia in this study was seen in 
33% of the bacteremic cases, which was much higher
than the 17% reported (12). Fifty-two per cent of these
cultures were from ICU patients. However, contamina-
tion may have been responsible for some of the cases.
Patients with polymicrobial bacteremia were clinically
worse and had a higher mortality rate compared to
patients with monomicrobial P. aeruginosa bacteremia
(12). In our study, however, 70% of patients with early
mortality had monomicrobial bacteremia with P. aeru-
ginosa. The most common organism isolated along 
with P. aeruginosa was Enterococcus spp. (12), whereas 
in our study, Staphylococcus aureus was the commonest
organism isolated, followed by Enterococcus spp.
It was not possible to determine with certainty the
source of bacteremia in our patients, but 47% of the
patients had a CBD catheter in situ and among those
in whom a presumed source of infection was found, a
urinary portal of entry was the commonest (11%),
followed by the respiratory tract (10%). Studies have
found that the respiratory tract was the commonest
source for P. aeruginosa septicemia (6).
Table 4. Sensitivity of P. aeruginosa to antimicrobials 
Antibiotic
CAZ CFP GM AN CIP IPM MEM* PIP P/T* SCF
Percentage sensitive 79 77 78 91 81 86 76 80 100 81
(No. tested) (109) (109) (109) (100) (109) (109) (49) (104) (25) (95)
Key:
S = sensitive
CAZ = ceftazidime, CFP = cefoperazone, GM = gentamicin, AN = amikacin, CIP = ciprofloxacin, IPM = imipenem, MEM = meropenem,
PIP = piperacillin, P/T = piperacillin/tazobactam, SCF = cefoperazone/sulbactam
* Number of strains tested against these antimicrobials were few as they were not part of the routine testing panel in our laboratory at the 
time of this study. Isolates were only tested against these antimicrobials if multi-resistant or if specifically requested for by the clinicians.
Table 3. Organisms isolated in polymicrobial cases
involving P. aeruginosa
Microorganisms No. of isolates
Gram-positive cocci
Staphylococcus aureus 6
(three isolates were methicillin 
resistant S. aureus)
Enterococcus spp. 5
Staphylococcus epidermidis 3
Gram-negative rods
E. coli 4
Stenotrophomonas maltophilia 2
Enterobacter spp. 3
Klebsiella spp. 4
Acinetobacter spp. 4
Pseudomonas spp. 1
Yeast 1
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Conclusion
This study has highlighted the common epidemiolo-
gical features of patients with P. aeruginosa bacteremia
in our hospital, but being retrospective and not case
controlled, firm statistical conclusions could not be
made. As only 87 of the 109 patients’ records were
available for analysis, any bias in results cannot be
excluded.
Most of our isolates were sensitive to imipenem, cipro-
floxacin, ceftazidime, gentamicin and cefoperazone and
for community-acquired isolates all were sensitive to
imipenem, ceftazidime, cefoperazone, and ciprofloxacin.
Therefore, if a P. aeruginosa septicemia was suspected or
confirmed in a patient in our hospital, these antimicro-
bials would probably be effective as empirical therapy
while awaiting results of sensitivity. Although not all
isolates were tested against amikacin, among those
tested, 91% were found to be sensitive. Four isolates
were found to be resistant to all antibiotics except
polymyxin B. Antibiotic selection for treatment of
infections caused by P. aeruginosa is often problematic
(4). In our study, 61% of patients with early mortality
had been on inappropriate empirical antimicrobials.
There have been conflicting reports about mortality in
relation to whether patients had received appropriate
or inappropriate antibiotics, with several studies failing
to show a difference (1,13,14) and others showing a
decrease in mortality when appropriate antibiotics
were used (15,16,17,18).
Nonetheless, it does seem prudent to start empirical
antimicrobials that are likely to be effective against 
P. aeruginosa if it is thought to be a likely pathogen,
particularly, when dealing with immunosuppressed
patients.
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Introduction
Basketball and netball are among the popular contact
sports in Malaysia. Netball evolved from a common
progenitor with basketball, and therefore, there are
similarities between the games. According to a study
carried out (1,2), female athletes in elite team sports
such as basketball and netball need a body fat per-
centage of 10% to 16% or skinfold value of 70-90 mm
(averaged from seven locations) to perform well or to
achieve their full playing potential.They reported that
players with body fat percentages of 12% to 16% had
better overall physical fitness, better movement and
tired less easily compared to players who were
reported to have skinfold values exceeding the ideal
level. Body fat in excess of 25% would limit the players’
movements. They would also be tired faster from
lugging the extra weight around. Moreover, more
oxygen would be needed to catabolize the fat for the
extra energy required (3).All these would lower their
level of play. Hence, the purpose of this study is to
compare the body fat percentage among elite
basketball and netball players in Malaysia, and to
identify whether the body fat value was in line with
the suggestion given (1,2).
BODY FAT COMPARISON BETWEEN BASKETBALL 
AND NETBALL PLAYERS IN MALAYSIA
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ABSTRACT: The aim of the study was to compare the body fat percentages between
Malaysian national women basketball players and netball players. Both basketball
and netball players were elite players who represented Malaysia in the 1997 Southeast
Asia Games in Jakarta, Indonesia and the 1998 Commonwealth Games in Kuala Lumpur.
The percentage of body fat was determined by means of skinfold measurement at
seven different locations. Results of the findings showed that overall, the basketball
players had higher percentages of body fat than netball players. The average percent-
ages of body fat of basketball and netball players were 19.68 ± 4.93% and 18.93 ± 4.41%,
respectively. Both Malaysian national basketball and netball players’ average per-
centage of body fat were found to be higher than the ideal average percentage of body
fat range between 10-16% for female athletes in elite team sports. The players in the
defence position in basketball were found to have the highest percentage of body fat
(23.00%), followed by centre position players (21.62%) and attack position players
(15.10%). These results differed from netball players’ in similar playing positions.
Among the netball players, the defence position players had the highest percentage of
body fat (21.00%), followed by attack position players (18.63%), and centre position
players (16.57%). (JUMMEC 2006; 9(1): 20-22)
KEYWORDS: Body fat, netball players, basketball players, playing position
Methods and Procedures
Subjects
Twenty-three physically active elite Malaysian basket-
ball (N=12) and netball (N=11) players were chosen
for this study.The basketball and netball players were
elite players who represented Malaysia in the 1997
Southeast Asia Games in Jakarta, Indonesia and the
1998 Commonwealth Games in Kuala Lumpur, respec-
tively. Players from both teams were elite players as
they were the best national teams in Malaysia, and
participated in the highest level of competition in their
respective games.The subjects were divided into three
categories, i.e., defender/guard, centre, and attacker/
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forward. The physical characteristics of the subjects
for the games are shown in Table 1.
Procedure and Instrumentation
The study was carried out at the Malaysian National
Sports Institute, Bukit Jalil.A trained physiologist, who
was working with the institute, took these measure-
ments. According to Tothill and Stewart, measure-
ments taken by trained personnel should be fairly
reliable (4). Seven locations were pinched – chest, mid-
axilla, subscapular, triceps, suprailiac, navel, and thigh –
using a Harpenden caliper. Seven skinfold location sites
were chosen because the more locations taken, the
more accurate the results would be (5). Furthermore,
more skinfold sites taken were also reported to have
higher correlation (r=0.85) with Hydrostatic Weighing
(6,7).The calculation of body fat content was based on
the formula (6).
Statistical Analysis
The overall and based on playing positions body fat
contents were reported in percentages and the body
fat comparison between both teams were done directly
based on the percentages (8). Besides that, both the
body fat percentage values obtained were also used to
determine whether they were in line with the
suggestion given (1,2).
Results
A mean body fat percentage of 19.68 ± 4.93% was
reported among the elite basketball players.The body
fat range in this study was 10.40% to 26.20% (Table 2).
The defence women basketball players had the highest
body fat percentage, followed by the centre and attack
players. The body fat percentages among the basket-
ball players based on the above playing positions were
23.00 ± 3.39% (defence), 21.62 ± 3.91 (centre), and
15.10 ± 4.12% (attack), respectively (Table 3). Mean-
while, the netball players had a mean of 18.93 ± 4.41%
body fat. The body fat range was from 13.20% to
25.70% (Table 2). Defence netball players had the
highest body fat percentage of 21.00 ± 4.89%, followed
by attack 18.63 ± 5.40%, and centre 16.57 ± 5.40%
position players (Table 3).
Table 2. Body fat percentages (%) among basketball and netball players 
Basketball Players Body Fat (%) Netball players Body Fat (%)
1 18.30 1 21.50
2 10.40 2 20.90
3 18.80 3 17.30
4 12.90 4 14.80
5 22.00 5 13.20
6 16.60 6 13.70
7 19.00 7 22.80
8 26.20 8 19.50
9 26.10 9 24.00
10 19.80 10 25.70
11 25.40 11 14.80
12 20.60
Body Fat Range 10.40 – 26.20% 13.20 – 25.70%
Mean and SD 19.68 ± 4.93 18.93 ± 4.41
Table 1. Mean values of physical characteristics for the basketball and netball players 
Teams N Age (years) Height (cm) Body Mass (kg)
Mean SD Mean SD Mean SD
Basketball 12 22.75 2.67 171.71 5.45 63.88 6.46
Netball 11 23.91 3.36 168.70 6.74 61.34 7.92
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Discussion
The overall body fat percentages of 19.86% and
18.93% among the Malaysian basketball and netball
players were found to be higher compared to the ideal
norm of 10% to 16% (1). However, there were two
basketball players and four netball players who had
body fat percentages within the 10% to 16% range.The
range of percentage of body fat among the Malaysian
basketball and netball players is between 10.40% to
26.20% and 13.20% to 25.70%, respectively (Table 2).
Results of this study also showed that there were
three basketball players and one netball player with
body fat percentages exceeding 25%. According to
research (1), body fat in excess of 25% would limit the
players’ movements. They would also become tired
faster from lugging the extra weight around.Moreover,
more oxygen would be needed to catabolize the fat
for the extra energy required (3). All these would
lower their level of playing performance and prevent
them from playing to their full potential (2). Mean-
while, for playing position, only attack basketball
players were found to have the most suitable body fat
percentage for a good basketball player.These players
had mean body fat percentage of 15.10% (Table 3).
Conclusion
The Malaysian elite women basketball and netball
players were found to have higher body fat percent-
ages compared to the elite basketball players’ norm of
10% to 16% (1). Of all the subjects, only two basketball
players and four netball players were found to have
suitable body fat percentages required to be a good
basketball or netball player. Most of the basketball and
netball players were found to have acceptable body fat
percentage, i.e., body fat less than 25%. However, three
basketball players and one netball player had body fat
percentages exceeding the 25% (Table 2), which is
considered high for elite national players (9). An above
average body fat was reported to have an impact on
running speed, jumping ability and endurance per-
formance (2).
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Table 3. Mean body fat percentage (%) based on playing position 
Teams Positions Overall
Attack SD Centre SD Defense SD Mean SD
Basketball 15.10 4.12 21.62 3.91 23.00 3.39 19.68 4.93
Netball 18.63 3.15 16.57 5.40 21.00 4.89 18.93 4.41
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Introduction
The novel or atypical anti-psychotic medications intro-
duced over the last decade represent a significant step
forward in pharmacotherapy. Risperidone (Risperdal®)
and olanzapine (Zyprexa®) are novel anti-psychotic
agents belonging to the new class of atypical anti-
psychotics that was first defined by the introduction of
clozapine. The exact mechanism of action of both
drugs has not been fully elucidated. It may involve
antagonism at serotonin type 2 (and type 3 and 6 for
olanzapine) and dopamine receptors (1).
While conventional anti-psychotics effectively reduce
psychotic symptoms, they often induce extrapyramidal
side effects and tardive dyskinesia. The atypical agents
are generally free of these unwanted effects and gen-
erally have a more favourable adverse-effect profile than
conventional anti-psychotics (2,3).Moreover, in addition
to effectively treating positive psychotic symptoms,
atypical agents are often helpful for patients unrespon-
sive to conventional agents and may be more effective
for negative symptoms and cognitive dysfunction.These
characteristics improve drug compliance and yield a
decline in the number of relapses and the need of
hospitalization (4,5).
While cost-effectiveness of atypical anti-psychotics
versus the conventional drugs has been extensively
documented and demonstrated, the relative cost-
effectiveness of the atypical anti-psychotics among
each other has not yet been widely investigated. A
study from North America suggests that olanzapine 
is associated with higher treatment costs (on average
twice as costly), while this is not compensated for by
any clinical advantage (6). The present study was a
single centre, retrospective comparative study. The
objective of this study was to compare the drug 
usage pattern, the costs and outcomes associated with
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costs, and outcomes associated with risperidone or olanzapine in a naturalistic clinical
setting. Retrospective chart reviews of 92 patients with psychotic disorders were
conducted at the University of Malaya Medical Centre (UMMC). Data was collected
from patients who were hospitalized and for whom risperidone or olanzapine was the
drug of first choice for long-term pharmacologic treatment.
Proportion of patients for whom efficacy of the studied treatment could be established
(as rated by the treating physician) was higher, but not significantly, with risperidone
compared to olanzapine (p = 0.46). The average dose of the studied medication was 
2.9 ± 1.0 mg/day for risperidone and 9.7 ± 2.4 mg/day for olanzapine. The total cost 
was significantly higher (p < 0.0001) for olanzapine (RM140.40; 95% CI: 108.4–181.9)
compared to risperidone (RM50.80, 95% CI: 39.5–65.3). The daily cost was also signi-
ficantly higher for olanzapine (RM19.16; 95% CI: 17.72–20.72) compared to risperidone
(RM4.95; 95% CI: 4.46–5.51, p < 0.0001). Analysis of responders showed significantly
higher daily and total costs of treatment with olanzapine compared to risperidone.
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treatment of psychotic disorders with either ris-
peridone or olanzapine within a single hospital setting
in Malaysia.
Methods
Study outline
Data was collected at the University of Malaya Medical
Centre (Malaysia) from patients who had been hos-
pitalized and for whom risperidone or olanzapine was
the first intended drug for long-term pharmacological
treatment after admission.
The total number of patients required within each
treatment group was 33.The most recent admissions
were systematically checked in reverse chronological
order and patients were included if the following
criteria were met:
1. Risperidone or olanzapine was the first intented
drug for long-term treatment;
2. Patient was not older than 65 years; and
3. The patient was discharged from the hospital
before 120 days.
The most recent patients treated by olanzapine and
the most recent patients treated by risperidone were
selected. Data regarding demography, history of psy-
chiatric illness (diagnosis, number of previous hospital-
izations), diagnosis upon admission, hospitalization
information (length of hospital stay, discharge status),
medication history, usage pattern of drugs used over
the length of stay in hospital, dose details of the study
treatments (risperidone and olanzapine, details of
other neuroleptics or other relevant concomitant
medications, treatment efficacy (efficacy assessment:
effective, ineffective or partially effective as rated by
the treating physician) and side effects related to
neuroleptics were collected.
Primary parameters (outcome measures)
The primary parameters were the average daily costs
of the drugs (Risperidone/Olanzapine) under study.
Secondary parameters (outcome measures)
The secondary parameters were the average daily
dose and cost of studied treatments (risperidone or
olanzapine), the time to discharge, the proportion of
patients who discontinued treatment and switched
from risperidone or olanzapine to other anti-psychotic
treatment, the treatment efficacy as rated by the
treating physician, the number of days before efficacy
was established and the side effect profile.
Patient populations
Two populations were considered:
1. The intention-to-treat (ITT) populations, consist-
ing of patients who had been treated with the
treatment to which they were assigned;
2. The responders, defined as patients whose treat-
ment was judged as effective by the treating
physician and who did not discontinue the treat-
ment for any reason except if the treatment was
no longer deemed necessary.
Data analysis
Dosage parameters were analyzed by descriptive
methods (mean, standard deviation, median, minimum
and maximum) without statistical comparison between
risperidone and olanzapine. Costs between treatments
were analyzed by descriptive statistics and compared
by using t-test on the log-transformed data because
log-normal distribution fits the data better than 
the normal distribution. The mean cost was sum-
marized by the geometric mean and its 95%
confidence interval.
Proportions of patients were compared between
treatments using Fisher’s exact test. Number of days
before efficacy was established, was compared using
the non-parametric Mann-Whitney rank test.
The time to event parameters (e.g., time to onset of
efficacy, time to discharge) was also analyzed using
survival analysis methods to take into consideration
censored data (patient for whom efficacy was not
reached). The Kaplan-Meier product-limit estimate of
the survival function was calculated and the com-
parison between treatments was carried out using
non-parametric tests (Generalized Wilcoxon test and
log-rank test).
Ethics
The study was approved by the University of Malaya
Medical Centre ethics committee. Consent was
obtained from patients prior to data collection.
Results
Ninety-two patients (Risperidone: 43, Olanzapine: 49)
were part of the study. There were 67 responders
(Risperidone: 35, Olanzapine: 32).Among the 25 non-
responders, the study treatment was rated as ineffec-
tive by the physician in 12 patients, the treatment was
rated as partially effective in ten others, and the
efficacy was not assessed in three patients.
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Demography and patient’s profile are summarized in
Table 1. Patients treated with risperidone were signi-
ficantly older at admission than those treated by
olanzapine (median: 35.9 vs. 29.5 years, respectively,
p = 0.02). The age at onset of first symptoms was
higher in the risperidone group than in the olanza-
pine group (median: 27.3 vs. 25.5 years, respectively).
However, the difference was not statistically
significant (p = 0.11).The proportion of females and
males was similar in both groups (p = 0.40). The
groups differed significantly regarding the pattern of
diagnosis (p = 0.002). There were proportionally
more patients with diagnosis other than schizo-
phrenia in the olanzapine group (bipolar: 33%; other
diagnosis: 31%) than in the risperidone group
(bipolar: 7%; other diagnosis: 16%).
Table 1. Demography and patient’s profile (ITT patients)
Parameter Risperidone (N=43) Olanzapine (N=49) p
Age at onset of first symptoms (y) 31.3 ± 14.9 27.2 ± 9.0 0.11
Age at admission (y) 39.1 ± 16.4 32.2 ± 11.3 0.02
Gender Males 18 (43%) 26 (53%) 0.40
Females 24 (57%) 23 (47%)
Diagnosis: 0.002
– Catatonic schizophrenia 1 (2%) 0
– Disorganised schizophrenia 1 (2%) 0
– Paranoid schizophrenia 23 (53%) 14 (29%)
– Undifferentiated schizophrenia 8 (19%) 4 (8%)
– Bipolar 3 (7%) 16 (33%)
– Other diagnosis 7 (16%) 15 (31%)
Previous hospitalization 22 (51%) 27 (55%) 0.83
Number of previous hospitalizations: 0.45
0 21 (49%) 22 (45%)
1 – 5 19 (44%) 25 (51%)
6 – 10 3 (7%) 2 (4%)
History of medication available 26 (60%) 27 (55%) 0.68
Use of anti-psychotics during 26 (100%) 27 (100%) –
the previous year (‡)
Number of previous anti-psychotics: (‡) 0.21
0 0 0
1 12 (46%) 9 (33%)
2 13 (50%) 14 (52%)
3 1 (4%) 4 (15%)
Number of patients who discontinued 
previous anti-psychotics: (§)
– for any reason 26 (100%) 26 (96%) >0.99
– for lack of efficacy 17 (65%) 19 (70%) 0.77
– for side effects 12 (46%) 12 (44%) >0.99
– for other reason(s) 4 (15%) 5 (19%) >0.99
Number of previous anti-psychotics 
discontinued: (‡) 0.7
0 0 1 (4%)
1 12 (46%) 11 (41%)
2 13 (50%) 11 (41%)
3 1 (4%) 4 (15%)
Values are numbers of patients (%) except for age: mean ± SD 
(‡): Percentages are calculated using the patients with available history of medications as denominator (N=26 and 27 patients for risperidone 
and olanzapine, respectively);
(§): Percentages are calculated using the patients who took previous anti-psychotics (N=26 and 27 patients for risperidone and olanzapine,
respectively).
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The proportion of patients with previous hospital-
izations was similar in both groups (p = 0.83). The
number of previous hospitalizations exceeded five
times in 7% of the risperidone patients and in 4% 
of the olanzapine patients. Of the patients with
available history of medication, there were 60% in the
risperidone group and 55% in the olanzapine group 
(p = 0.68). Of these patients, all in both groups had
used anti-psychotics in the previous year.The number
of previous anti-psychotics used by patients was
similar in both groups (p = 0.21). The proportion of
patients who discontinued previous anti-psychotics
was also similar in both groups. Reasons for discon-
tinuation were lack of efficacy in 36 patients (Risperi-
done: 17; Olanzapine: 19), side effects in 24 patients
(12 in each group), and other reasons in nine patients
(Risperidone: 4; Olanzapine: 5). Based on the list of
previous anti-psychotics, only one olanzapine patient
was already treated with the medication under study
when admitted at the hospital.
Main parameters of interest are summarized in the
Table 2. Proportion of patients for whom efficacy of
the treatment could be established (as rated by the
treating physician) was higher with risperidone (81%)
than with olanzapine (70%). However, the difference
was not statistically significant (p = 0.46).The number
of days before treatment efficacy was established was
similar in both groups (median: 6.0 days for both treat-
ments, p = 0.60).The difference between groups in the
curve of the time to efficacy distribution function
(including censored observations) was not statistically
significant (p ≥ 0.59, Figure 1).
The average daily dose was 2.9 mg/day for risperidone
patients and 9.7 mg/day for olanzapine patients. The
study treatment duration was slightly longer in the
risperidone group than in the olanzapine group (10.2
vs. 7.3 days, respectively). However, the difference
reached a statistical tendency (p = 0.07).The average
daily cost of the medication was significantly higher for
olanzapine than for risperidone (Ringgit Malaysia (RM)
19.16 vs. RM4.95, respectively, p < 0.0001). The total
cost of treatment was significantly higher for olanzapine
than for risperidone (RM140.4 vs. RM50.8, respectively,
p < 0.0001). When considering the responders only
(Table 3), the results also showed significantly higher
daily and total costs of treatment with olanzapine
compared to risperidone.
Utilization of other neuroleptics and other relevant
concomitant medications (anti-epileptics, anti-Parkinson,
anxiolytics, hypnotics and sedatives, and anti-histamines)
is summarized in Table 4. The proportion of patients
who took at least one other neuroleptic or one other
relevant concomitant medications (started at any time)
Table 2. Main parameters of interest (ITT patients)
Parameter Risperidone (N=43) Olanzapine (N=49) p
Number of patients 43 (100%) 49 (100%) –
Number of patients with effective treatment (§) 35 (81%) 32 (70%) 0.46
Number of days before efficacy was established (‡) 6 (1–21) 6 (2–14) 0.60
Number of patients who discontinued the treatment 0 1 (2%) >0.99
Average daily dose (mg) 2.9 ± 1.0 9.7 ± 2.4
Study treatment duration (days) 10.2 (8.4; 12.5) 7.3 (5.9; 9.1) 0.07
Total cost (RM) of treatment drug 50.8 (39.5; 65.3) 140.4 (108.4; 181.9) <0.0001
Daily cost (RM) of treatment drug 4.95 (4.46; 5.51) 19.16 (17.72; 20.72) <0.0001
Values are patient numbers (%) except for dose: mean ± SD, number of days before efficacy: median (minimum – maximum) and costs and 
study treatment duration: geometric means (95% confidence interval).
(§): Efficacy of three olanzapine patients was not assessed (N=43 for risperidone, N=46 for olanzapine);
(‡): Statistics are calculated on the patients whose efficacy was established (N=35 for risperidone, N=32 for olanzapine).
US$ = RM3.80
Table 3. Main parameters for responders
Parameter Risperidone (N=35) Olanzapine (N=32) p
Average daily dose (mg) 2.9 ± 0.9 9.5 ± 1.9
Study treatment duration (days) 11.3 (9.1; 14.1) 10.2 (8.4; 12.5) 0.58
Total cost (RM) of treatment drug 56.7 (43.8; 73.5) 195.2 (150.5; 253.2) <0.0001
Daily cost (RM) of treatment drug 5.01 (4.50; 5.58) 19.09 (17.48; 20.85) <0.0001
Values are geometric means (95% confidence interval) except for dose: mean ± SD.
JUMMEC 2006: 9(1)
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was similar with both treatment groups (93 vs. 90% for
risperidone and olanzapine, respectively, p = 0.72).The
proportion of patients who started at least one other
neuroleptic or one other concomitant medication at
different times was also similar in both groups. When
considered separately, the two treatment groups were
not significantly different with regards to the propor-
tion of patients who started on other neuroleptics or
other relevant concomitant medications.
Table 5 shows the characteristics of hospitalization of
the responders.Among responders, the total duration
of hospitalization was longer in the risperidone group
than in the olanzapine group (mean: 18.3 vs. 15.2 days,
Table 4. Use of other neuroleptics and other concomitant medications
Parameter Risperidone (N=43) Olanzapine (N=49) p(*)
Number of patients who took other neuroleptics
Pre-existing of Ris./Ola. treatment 25 (58%) 30 (61%) 0.83
Since initiation of Ris./Ola. treatment 7 (16%) 4 (8%) 0.34
After initiation of Ris./Ola. treatment 1 (2%) 1 (2%) >0.99
Number of patients who took other relevant 
concomitant medications
Pre-existing of Ris./Ola. treatment 21 (49%) 19 (39%) 0.40
Since initiation of Ris./Ola. treatment 8 (19%) 10 (20%) >0.99
After initiation of Ris./Ola. treatment 4 (9%) 6 (12%) 0.75
Number of patients who took other neuroleptics 
or concomitant medications
Pre-existing of Ris./Ola. treatment 31 (72%) 32 (65%) 0.51
Since initiation of Ris./Ola.Treatment 13 (30%) 10 (20%) 0.34
After initiation of Ris./Ola.Treatment 5 (12%) 7 (14%) 0.77
(*): Probability associated with no difference between treatments (Fisher’s exact test).
Table 5. Characteristics of the hospitalization (responders) 
Parameter Risperidone (N=35) Olanzapine (N=32) p(*)
Total duration (days) 18.3 ± 14.5 15.2 ± 8.2 0.66
Duration of studied treatment (days) 14.0 ± 10.6 11.9 ± 6.9 0.58
Time (days) between admission 4.4 ± 11.0 3.3 ± 4.0 0.60
and start of treatment (0; 1.0; 64) (0; 1.5; 15)
Length of stay in each ward (days)
– Psychiatric 18.3 ± 14.5 14.3 ± 8.4 0.40
Discharge
Number of patients discharged 35 (100%) 32 (100%) – 
before or at day 120
N patients discharged vs. location: >0.99
– Another hospital 2 (6%) 1 (3%)
– To own home 32 (91%) 31 (97%)
– Other 1 (3%) 0
Time to discharge:
Time estimate (95% CI) for discharge of 0.41 (1)
25% of patients 9.0 (8; 12) 9.5 (8; 12) 0.66 (2)
50% of patients 13.0 (11; 20) 13.5 (10; 16)
75% of patients 21.0 (15; 28) 19.5 (15; 22)
(*): Probability associated with the hypothesis of no difference between treatments (t-test for weight, Mann-Whitney rank test for duration and lengths
of stay, Fisher’s exact test for number of patient discharged, and log-rank test (1) and Wilcoxon test (2) for survival analysis of time to discharge).
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respectively).The difference was not statistically signi-
ficant (p = 0.66). This pattern was also true in the
actual treatment; duration of risperidone was longer
than olanzapine (mean: 14.0 vs. 11.9 days, respectively).
The difference was also not statistically significant 
(p = 0.58). In the time between admission and start of
treatment, no statistical difference between groups
was found (mean: 4.4 vs. 3.3 day for risperidone and
olanzapine, respectively, p = 0.60).
As observed in the ITT population, all responders in
both groups were discharged before 120 days. Most
patients were discharged to their own home (91% and
97% for risperidone and olanzapine, respectively).The
Figure 1. Time distribution function of the time (days) to onset of efficacy
Figure 2. Time distribution function of the time to discharge of responders
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estimate median time to discharge of patients was
similar in both treatment groups (13.0 vs. 13.5 days for
risperidone and olanzapine, respectively). Moreover,
the difference between study groups in the curve of
the time to discharge distribution function was not
statistically significant (p ≥ 0.40) (Figure 2).
Discussion
An episode of psychosis is usually managed through
hospitalization and use of anti-psychotic therapies.
There is no evidence that really shows one atypical
anti-psychotic having better efficacy than the other
(7).Therefore, a pharmacoeconomic assessment would
primarily be a comparison of the direct costs asso-
ciated with their administration. The most important
driver of costs is probably the drug acquisition costs,
which are determined by the actually used dosage
schedules of the anti-psychotics and by the need for
concomitant medication.Another driver of costs may
be the length of hospitalization.
Within this cohort of patients, treatment with rispe-
ridone was associated with significantly lower cost
compared with olanzapine with no compensation in
efficacy and safety. The data suggests that treatment
with risperidone may be more cost-effective than
treatment with olanzapine. However, there is a clear
need to confirm these findings with further retro-
spective studies in other patient groups and with
prospective, randomized, naturalistic studies that
would accurately reproduce the clinical conditions in
which these agents are used.
Our study has several limitations that must be taken
into consideration. By definition, our retrospective
study’s most obvious limitation is that it is unmasked
and unrandomized.The retrospective study design has
the potential to compare incomparable groups through
some sort of treatment allocation bias. If such a bias
was in operation, we would expect to see noticeable
differences in patient profiles between treatment
groups that would predict the superiority of one
treatment over the other. In this study, there is a
significant difference in the age of admission that
definitely needs consideration. The earlier the age of
contact, the more likely it is to have a poor prognosis.
There also has been significant difference in the
diagnosis.This could affect the conclusions.
Conclusion
The duration of the study is too short for any sig-
nificant conclusion on cost-effectiveness. A longer
duration would have been more appropriate to see
actual effects and side effects that might occur. Despite
these limitations, the retrospective study does have
the advantage of collecting real-world data beyond the
artificial framework that a randomized clinical trial
may impose.
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Introduction
Globally, approximately 210 million women become
pregnant and some 130 million give birth. Although
most of these pregnancies are uneventful, an estimated
15% develop complications, and about one-third of
these have life threatening consequences. Com-
plications related to pregnancy and childbirth result 
in more than half a million deaths and 99% of 
them occur in developing countries (1). Every minute
somewhere in the world, a woman dies from com-
plications in pregnancy and childbirth.The majority of
these deaths are avoidable (2). In some developing
countries, the lifetime risk of maternal deaths may be
as high as one in seven, when compared to one in
5,000 in many developed countries. This disparity of
more than a hundredfold in maternal deaths reflects
the tragic status between developed and developing
countries (3). Maternal mortality has been a neglected
problem globally for so long due to inadequate infor-
mation. Countries with the highest levels of mortality,
seldom have reporting of vital events such as births
and deaths. In the mid-1980s, a number of community
surveys, many of which were supported by WHO
brought to light the size of the problem but the signi-
ficance of maternal deaths remains largely ignored and
unattended.
In Malaysia, the maternal mortality ratio declined 
from 530 per 100,000 live births in 1957 to 148 per
100,000 in 1970 and 30 per 100,000 live births in 
2000 (4). There has been a significant decline in the
reduction of maternal mortality in this country in 
the last 50 years (Figure 1). The decline in maternal
mortality has been due to the introduction of various
programmes in the area of reproductive health since
the 1950s. Have we reached the minimum limit of
maternal mortality or can we reduce it further? The
answer lies to a large extent in the measurement of
maternal mortality. Are we measuring maternal
mortality accurately or do we need to relook at the
way we measure maternal mortality? There is a prob-
ability that if we are able to capture all maternal
deaths, Maternal Mortality Ratio (MMR) may be much
higher than what it is now. This study proposes to
identify the problems of measuring maternal mortality
and suggest ways as to how we can further measure
MMR more accurately.
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ABSTRACT: There has been a significant decline in maternal mortality in Malaysia
since independence. The issue of measuring maternal mortality accurately is a problem
in all countries. Another major problem is whether we can reduce the mortality
further. The definition of maternal mortality includes two major components, which
are causation of death and the time of death. To improve data collection on maternal
deaths, we need to collect all data on maternal deaths, which are omitted or mis-
classified. Deaths from accidental causes that are not normally used in the calculations
of maternal mortality need to be carefully reexamined to be excluded. The time of
death means that in maternal mortality calculations, it includes up to six weeks after
delivery, but recent World Health Organization (WHO) publication (ICD-10) suggests
that the collection of maternal deaths even after six weeks should be reviewed because
there are many maternal deaths which occur after six weeks. Measuring maternal
mortality rate should be encouraged rather than maternal mortality ratio. Another
measurement of maternal mortality is the lifetime risk of the women. The lifetime risk
is the measure of maternal mortality that takes into account the probability of becoming
pregnant and the probability of dying as a result of pregnancy. Many countries have
started reporting the lifetime risk, which is considered to be better indicator to
measure maternal health. (JUMMEC 2006; 9(1): 30-34)
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Background
Maternal death is defined as the death of a woman
while pregnant or within 42 days of termination of
pregnancy, irrespective of the duration and the site of
the pregnancy, from any cause related to or aggravated
by the pregnancy or its management but not from
accidental or incidental cause (5).The direct obstetric
deaths resulting from complications arising during
pregnancy, labour or during the post-partum period
deaths may result from interventions, omissions,
incorrect treatment or from a chain of events result-
ing from any of the above. The indirect obstetric
deaths result from previous existing disease or
diseases, which develop during pregnancy, e.g., heart
disease and diabetes. The accidental or coincidental
deaths are deaths due to accidents such as road
accidents or drowning of a pregnant women (1).
About 80% of all maternal deaths in the world are 
due to direct cause which are complications arising
during pregnancy, delivery and during the first six
weeks after birth. The five main causes of maternal
deaths in the world are haemorrhage (25%), sepsis
(15%), eclampsia (12%), obstructed labour (8%) unsafe
abortion (13%) and indirect causes account for 20% 
of all deaths (2). Unsafe abortion accounts for more
than a third of maternal deaths in some parts of the
world. About 20% of the remaining maternal deaths
are due to indirect causes.Anaemia is one of the most
significant causes and the other indirect causes are
malaria, hepatitis, heart disease and HIV/AIDS. The 
low status of women limits women’s access to eco-
nomic resources and education. Poor nutrition before
and during pregnancy contributes to poor health,
obstetric problems and poor pregnancy outcomes for
both women and their newborns.
In Malaysia, reports from the Confidential Enquiry 
into Maternal Deaths (CEMD) during a four-year
period of 1991-1994, found that the most common
cause of maternal mortality was post-partum haemorr-
hage (PPH) (24.9%) followed by hypertensive disease 
of pregnancy (HDP) (16.3%), obstetric embolism
(12.4%), and associated medical conditions (10%),
birth trauma was 6.4% and puerperal sepsis was 6.1%.
The indirect maternal deaths were responsible for
10.5% of the total maternal deaths for the same
period (6).
Reliability of maternal mortality rates
Theoretically, maternal mortality rate is the number of
maternal deaths (numerator) to the total number of
pregnancies (denominator) per 100,000 pregnancies.
Figure 1. Maternal mortality ratio by year
Source: Vital Statistics Time Series (1911-1985) Department of Statistics Kuala Lumpur and Ministry of Health, Family Health Unit Annual Report 1998
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However, in practice, it is very difficult to get the exact
number of pregnancies.Therefore, what is measured is
actually the maternal mortality ratio and not the
maternal mortality rate in the comparison of maternal
deaths to total births. Maternal mortality rate is
difficult to obtain because the denominator of exact
number of pregnancies including live births, foetal
deaths, stillbirths, induced and spontaneous abortions,
ectopic and molar pregnancies are difficult to obtain.
Therefore, total births as a proxy denominator for the
total number of pregnancies are used.
Maternal Mortality Ratio is also an underestimate due
to poor vital registration of maternal deaths. Many
deaths go unregistered and uncertified.Although some
countries have a good registration system, the poor
classification of death makes the validity of the
maternal mortality rate questionable.
The MMR measures a woman’s chances of dying from
a given pregnancy. For example, if a pregnant woman
who has a miscarriage during the first 28 weeks, does
not register the deaths of the foetus. If she has not
registered for pre-natal care, she may be missed in the
denominator, thus, affecting the MMR rate. Also
pregnancies that result in death of the foetus after 
28 weeks are also often not registered. In some
underdeveloped countries, the registration of births
and death may not be easily available due to poor
accessibility and cost of travel to make a report. The
mothers also do not regard this issue as important.
Pregnancy is also seen as a private matter in some
societies and as such terminations and abortions may
not be reported. It is very difficult to know the exact
number of pregnancies and therefore live births, which
is easily available is used as the denominator. Live
births are therefore considered a reasonable proxy
indicator of pregnancies in an area.
Problems in maternal mortality measurement
There are two problems in the definition; one, that is
related to the time of death and the second, to the
cause of death. With regard to the time of death,
historically MMR was defined as deaths occurring
within six weeks of pregnancy. This six weeks timing
was sanctioned by a variety of practices both religious
and cultural. There is no scientific basis for this six
weeks period (7). However in modern day medicine,
life can be sustained longer with better procedures
and techniques, which can prolong dying and delay
death. Even before the era of modern medicine, it is
likely that death took place beyond the six weeks
interval but the proportion was very small. Medical
procedures may increase that proportion but it is
likely to remain fairly small although by no means
negligible. The Centre for Disease Control and Pre-
vention reported that 29% of maternal deaths
occurred after 42 days of pregnancy termination and
about 6% occurred 90 days post-partum (7). The ICD-
10 therefore, introduced a new category called the
“late maternal death, which is defined as death of a
woman from direct or indirect obstetric causes more
than 42 days but less than one year after termination
of pregnancy.”
The second problem with the definition of maternal
death, lies in the classification of the cause of death.
Omission of maternal deaths can be due to the fact
that pregnancy and abortion are concealed.There can
be also a misclassification of maternal deaths between
maternal and non-maternal deaths and also obstetric
and incidental deaths. Sometimes, even the cause of
death is ill-defined and difficult to categorize.Accord-
ing to ICD-9 and ICD-10, maternal deaths are divided
into two groups, i.e., direct obstetric death and indirect
obstetric deaths.The drawback of this definition is that
the maternal death can escape being classified as being
the precise cause of death. Deaths from “accidental or
incidental causes” have historically being excluded
from maternal mortality. However, in practice, the dis-
tinction between incidental and indirect cause of
death is difficult to make. It is likely that many homi-
cides and suicides of pregnant women may be classi-
fied as accidental or fortuitous but in actual fact, it
could be due to the embarrassment of premarital
pregnancy or that the pregnancy may have produced a
child of the wrong sex.Thus, the suicide or homicide
examination has to be done in detail to ascertain that
it is excluded in the measurement of MMR (7). Deaths
missed due to causation in some countries ranged
from 22% in England and Wales to about 70% in Egypt,
Jamaica and Puerto Rico (8).
Changes related to MMR in ICD-10 (7)
There is very little change in the definition in the 
ICD-9 and ICD-10 codes for classifying causes of
maternal deaths. The Tenth Revision of International
Classification of Diseases (ICD-10) defines MMR
similar to the ninth revision. The Ninth International
Classification of Diseases (ICD-9) classified the com-
plications of pregnancy, childbirth and the puerperium
into five broad classes:
1. Pregnancy with abortive outcome (630-639),
2. Complications related to pregnancy (640-648),
3. Normal delivery and other indications for care in
pregnancy, labour and delivery (650-659),
4. Complications occurring mainly in the course of
labour and delivery (660-669), and
5. Complications of puerperium (670-676).
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However, the Tenth International Classification of
Disease (ICD-10) has divided the pregnancy-related
problems into eight blocks, covering slightly different
group of diseases.They are:
1. Pregnancy with abortive outcome (000-008),
2. Oedema, proteinuria and hypertensive disorders
of pregnancy, childbirth and puerperium (010-016),
3. Other maternal disorders predominantly related
to pregnancy (020-029),
4. Maternal care related to the foetus and amniotic
cavity and possible delivery problems (030-048),
5 Complications of labour and delivery (060-075),
6. Delivery (080-084),
7. Complications predominantly related to the puer-
perium (085-092), and
8. Other obstetrical complications not elsewhere
classified.
There is an increase of three more categories accord-
ing to ICD-10 as compared to ICD-9 and this will
make comparison of data very difficult within the
country and also between countries.The ICD report-
ing system also assumes a single cause of death
although there is a chain of events to the final cause of
death. Only a single cause of death is reported and the
cause is very subjective.There is a possibility that the
cause of death may be misclassified.This misclassifica-
tion may also reduce the maternal mortality further.
Discussion
Although there has been a significant decline in
maternal mortality in Malaysia, the actual rates may be
higher.All maternal deaths in all wards in the hospitals
need to be reviewed to exclude the possibility of
missing maternal deaths.This is to make sure that we
do not miss the maternal deaths that have died in
medical, surgical or other wards due to direct or
indirect causes and have been misclassified. This will
provide more accurate MMR in the country. A con-
certed effort is mandatory to include all maternal
deaths that are missed by omission, misclassification of
deaths and also deaths that are ill-defined is necessary
to avoid any missed deaths. All the incidental or
accidental death currently classified, must be con-
firmed to exclude it as a maternal death.Although the
Ministry of Health Confidential Enquiry into Maternal
Death (CEMD) does this, it must be clear the acci-
dental maternal deaths are really accidental deaths 
and only then they can be excluded from the MMR
calculations. Careful reviews may mean that some of
the incidental deaths may be included in the MMR
calculation. Countries that do not have the regis-
tration of births and deaths sometimes use special
surveys and other methods to measure maternal
mortality.
Malaysia has a good database and it needs to address
the issue of missing deaths and take into consideration
the new ICD-10 proposal of including those maternal
deaths beyond 42 days. In countries where the
maternal mortality is high, the bias introduced by the
inclusion of accidental or incidental causes is usually
low. In rural Bangladesh, where the overall mortality
rate is 570 per 100,000 live births, it was found that
90% of the deaths were due to direct and indirect
maternal causes. Therefore, the issue of incidental
maternal deaths is less (7). However, in Malaysia where
the maternal mortality rate is 20 per 100,000 live
births and direct and indirect account for 78.5% and
incidental deaths account for 21.4%, there is a need to
review all accidental deaths more seriously.
To overcome this problem of causation of deaths, the
ICD-10 has suggested a new category “the death of a
woman while pregnant or within 42 days of termina-
tion of pregnancy, irrespective of the cause of death”.
ICD-10 has also introduced the late maternal death
category which is defined as the death of a woman
from direct and indirect obstetric cause more than 
42 days but less than one year after termination of
pregnancy. This is to recognize the cases, which may
die due to pregnancy causes after 42 days of birth.We
may have missed some of the maternal deaths due to
this cause. It was found in the state of Georgia in US,
that 29% of maternal deaths occurred after 42 days 
of pregnancy and 6% occurred after 90 days over the
period of 1974-75.We have to look at maternal deaths
after 42 days to see whether they are related to
maternal deaths.
Conclusion
With the confusion in the use of the terms ratio and
rate, a proposed ideal measure is the lifetime risk.The
concept of lifetime risk is another way in which some
countries are measuring maternal mortality and it is
important that we adopt this concept.This takes into
account both the probability of becoming pregnant
and the probability of dying as result of pregnancy
cumulated across a woman’s reproductive years – the
lifetime risk.The product of the total fertility rate and
the maternal mortality ratio can also approximate it.
This concept is becoming increasingly popular in
developed countries and we should seriously consider
applying this concept in our country.With the imple-
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mentation of some of these ideas, we may be able to
get a more accurate maternal mortality data and
therefore address the problem of inaccurate maternal
mortality measurement in the country.
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Introduction
Road accidents have been emerging as one of the
leading cause of fatalities in the world today. In 1998,
it was the tenth Leading Cause of Death; causing more
than one million fatalities (1). The World Health
Organization has forecast that, by the year 2020, road
accidents will be the second most common cause of
premature death in the world (1).
In Malaysia, road traffic injuries were responsible for
45.8% of hospitalization and 68.9% of injury deaths in
government hospitals. Every day about 15 people die
on the road (2).
Commercial vehicle drivers spend a lot of time on the
roads. Some of them have to operate large and long
vehicles, which are more difficult to manoeuvre during
stopping, acceleration, and lane changing, and difficult
in judgement of clearance for both height and length.
These vehicles will have a greater potential for damage
and injury in cases of road accidents.
The reasons for road traffic accidents can broadly be
divided into three; those related to the road user,
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vehicle design and road environment (3,4). The factors
that are related to the road user include those due to
the drivers and pedestrians. The drivers’ factors are
annual mileage, fatigue and inattention, age, intoxica-
tion and speeding (5).
Many medical conditions, including vision impairment
had been associated with road traffic accidents (6,7,8,
9,10,11,12,). Vision plays a very important role in 
safe driving, it is often said that approximately 90% to
95% (13,14) of the sensory input to the brain required
for driving comes from vision.With this much at stake
that is why visual acuity had been a key issue in the
issuing of driving licences in many countries.
Vision requirement for driving
Different countries have different visual standards 
for private and commercial vehicle drivers (15,16,17,
ABSTRACT: A cross-sectional survey of commercial vehicle drivers who were renewing
their own licences was conducted at the Selangor Road Transport Department office in
Padang Jawa between 1 February 2002 and 28 February 2002, using questionnaire and
medical examination. The objective was to determine the prevalence of myopia, colour
vision deficiency and visual field defect among the commercial vehicle drivers. The
respondents that reported visual defect at the time of interview was compared with
those detected by the author through medical examination. Out of the 223 respon-
dents, 21 (9.4%) reported to have myopia by the questionnaire survey. Through the
visual examination there were 63 (28.3%) with myopia (visual acuity worse than 6/12),
six (2.6%) had a visual field defect and 14 (6.3%) had red-green colour deficiency. 
The visual defect detected during the study among the commercial vehicle drivers,
which were missed at the time of the routine medical examination were significant.
The process of the statutory medical examination should be reviewed. (JUMMEC 2006;
9(1): 35-38)
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18,19). In this study the author only looked at factors
that had been established by the Road Transport
Department (RTD) of Malaysia, which included visual
acuity for distant visual defect (myopia), colour vision
and visual field (20).
All drivers in Malaysia are required to possess a valid
driving licence in its class. There is no prior medical
examination for driving private vehicles; the drivers
are only required to read the licence plates test and
colour plates during the learners’ licence test. Com-
mercial vehicles drivers would have to undergo annual
medical screening before they are allowed to renew
their vocational licences. Medical practitioners regis-
tered with the Malaysian Medical Council (MMC) per-
form this medical screening after which they will have
to endorse the JPJ L8A form from RTD stating that the
driver is medically fit to drive commercial vehicles.
The visual acuity requirements stated in the guideline
from RTD, are minimum of 6/60 in each eye without
glasses and 6/12 or better in each eye with corrective
glasses. Commercial vehicle drivers who need cor-
rective glasses for driving need to declare this in their
driving licences. The other visual requirements are
normal colour vision and a normal field of vision.
Materials and Methods
A cross-sectional descriptive study on the prevalence
of myopia among the commercial vehicle drivers was
conducted at the Selangor State RTD Office in Padang
Jawa. Commercial vehicle drivers who were renewing
their own vocational licences between 1 February
2002 and 28 February 2002 were selected as the study
population.Those who were applying for new licences
were excluded. The interview and the vision exami-
nation were conducted by the author at the RTD
office. The vision examinations included visual acuity
examination using the Snellen Charts (alphabet or the
illiterate E chart), colour vision using Ishihara Chart
and visual field examination using the Humphrey
Perimeter. Data management and analysis were done
using the SPSS (Version 10.0).
Results
Characteristics of respondents
There were 223 drivers who responded to the ques-
tionnaire and the medical examinations. None of the
drivers approached by the author refused to co-
operate. All of the respondents were male. Their
ethnic group distribution is shown in Table 1.The mean
age of the respondent was 36.3 years (SD 7.8) and
range from 22 years to 58 years.
Statutory medical screening
Out of the 223 respondents, seven (3.1%) reported that
their medical screening was not carried out, and their
doctors had only endorsed the RTD medical forms.
Previous medical conditions
Out of the 223 respondents, six (2.7%) were known to
suffer from diabetes mellitus; five were on oral medi-
cations and one on sub-cutaneous insulin injection.
Seven (3.1%) had hypertension and were on regular
medication. None of the respondent reported to have
either epilepsy or cardiovascular diseases.
Seven (3.1%) had defective colour vision, 21 (9.4%) had
myopia and 14 (6.3%) had presbiopia. Five of the res-
pondents had pterygium and one had squint. None of
the respondents has cataract or glaucoma. Out of the
21 respondents who were known to have myopia, only
14 were using their corrective glasses while driving.
Medical examination
During the medical examination the author detected
52 with visual acuity of worse than 6/12; for those 
that used corrective glasses, visual acuity tests were
performed with their corrective glasses. Seventeen
respondents had visual acuity of worse than 6/12 in
the right eye alone and ten had visual acuity of worse
than 6/12 in the left eye alone.Twenty-five had visual
acuity worse than 6/12 in both eyes.Two respondents
had visual acuity of 6/60 in the right eye and two
respondents had visual acuity of 6/60 in the left eye.
One of the respondents had visual acuity of 6/60 in
both eyes.
Out of the fourteen that used corrective glasses, three
had visual acuity of worse than 6/12 in either one eye
even with their corrective glasses. When comparing
ethnicity and visual defect, the Chinese has the highest
percentage of visual defect (47.8%) compare to other
races (Table 2), the result are comparable to other
studies (21, 22, 23). Six respondents (2.6%) had a visual
field defect and 14 (6.3%) had red-green colour
deficiency.
Table 1. Ethnic group distribution of respondents
Ethnic Total Percentage
Malay 138 61.9
Chinese 23 10.3
Indian 51 22.9
Others* 11 4.9
Total 223 100
* The others stated in the table included 8 Indonesians, one Kadazan,
one Kampuchean, and one Pakistani. All the respondents were
Malaysian nationals.
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Table 2. Race and visual defect
Visual Race (percentage) Total
Defect* Malay Chinese Indian Others
No 106 12 36 6 158
(76.8) (52.2) (70.6) (54.5) (71.7)
Yes 32 11 15 5 63
(23.2) (47.8) (29.4) (43.5) (28.3)
Total 138 23 51 11 223
(100) (100) (100) (100) (100)
* Visual defect includes those who wear glasses as stated in questionnaire
and has visual acuity of worse than 6/12.
Adequacy of statutory medical examination
The author used visual acuity as an indicator for ade-
quacy for statutory medical examination. Comparing
the prevalence of reported myopia and the results of
visual acuity examination, taking visual defect to be
worse than 6/12.When people with myopia who used
corrective glasses were excluded from the results, the
author found that there is a significant difference
between the result of the visual acuity examination
and the reported myopia (Table 3). The medical exa-
mination revealed 49 of the respondents with visual
acuity worst than 6/12 and five respondents who had
visual acuity of 6/60 were missed during the statutory
medical screening. This indicated that the statutory
medical examination had failed to detect a significant
number of drivers who had myopia.
Table 3. Myopia (from statutory medical screening)
and visual defect* detected by examination
Myopia Visual Acuity Defect Total
No Yes
No 157 45 202
Yes 3 4 7#
Total 160 49 209
Measurement of Agreement:
Kappa 0.089, Std Error = 0.057, Sig = 0.032
* Visual acuity defect is taken as visual acuity worst than 6/12 when reading
the Snellen chart at 20 feet (six meter).
# The 14 individuals with myopia and wear corrective glasses have been
excluded from the findings.
Discussion
A total of  223 drivers were interviewed; their ages
were between 22 and 58, with the majority less than
40 year old.
Myopia
In this study, the author found 63 (28.3%) drivers 
with myopia.This includes the 14 who wore corrective
glasses. Of those who wore corrective glasses, 11 had
visual acuity of 6/12 or better with the corrective
glasses and three had visual acuity worse than 6/12.
The result is comparable to the study done on young
males in Singapore, which is 30.4% (23), but in another
study on 110,236 Singaporean males, the percentage 
is higher at 44.2% (24).
Statutory medical examination 
The results of this study showed that the statutory
medical examination had failed to detect a significant
number of drivers with myopia and other visual defects.
The statutory medical examination also missed a
driver with insulin-dependent diabetes mellitus, which
should have been disqualified under the RTD guide-
lines and JPJ L8A (20) forms.
The above result showed that although statutory
medical examinations were required for the commer-
cial vehicle drivers, the medical examinations con-
ducted were not up to the required standard. The
examination failed to reveal diseases that were not
allowed by law to drive commercial vehicles.This can
be serious, as other studies have shown an association
between such medical conditions and road accidents.
One possible reason for the failure of the medical
practitioner to conduct a more thorough medical
examination may be due to the fact that fees for each
medical examination was only between RM5 and
RM15 (US$1 = RM3.80), although a thorough medical
examination would takes at least 20 minutes to
conduct.The Malaysian Medical Council Fee Schedule
1997 recommended the fees for medical examination
for commercial vehicle drivers to be RM50 (25).
Another reason could be that the medical practitioner
may not be aware of the minimum medical require-
ment for commercial vehicles drivers as the visual field
test requirement was not stated clearly in the RTD
guideline.
Conclusion
This study confirms that the prevalence of visual defect
among the commercial vehicle drivers are similar to
that of earlier studies on normal population within this
region. It appears that many of the drivers are not
aware of defects in their vision despite having under-
gone a thorough medical examination. Furthermore,
those who were aware of their visual defect did not
correct the defect, and were still driving with vision
that do not meet the standard RTD requirements.
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The authority should look into this matter and revise
the format and form of the statutory medical
examination as this can be detrimental to the safety of
road users.
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Introduction
Acute chest pain in the adult is a frequently encountered
symptom in all healthcare settings (1).The diagnosis of
angina is occasionally not as straightforward as it would
appear and in many cases, classical electrocardiogram
findings (ECG) of angina may not be evident early on.
However, there is broad consensus that lifestyle
factors, including physical activity and diet, are funda-
mental determinants of heart disease risk (2).
In recent years, there has been renewed interest in
neural networks in cardiovascular diseases, particularly,
ischaemic heart disease. The majority of this research
has concentrated on the use of neural networks in
diagnosing acute myocardial infraction (AMI) and almost
all have used biochemical markers and ECG findings in
concert with the history and physical examination.
Ellenius and Groth (3,4) investigated neural networks in
the assessment of biochemical markers in AMI. Work 
conducted (5) and in the Heart Disease Program (6)
have contributed much to the use of artificial intelligence
(AI) techniques in chest pain diagnosis.
Studies have shown very good results with neural
networks in the diagnosis of AMI using just patient-
reportable factors and comparing favourably with
DIAGNOSING ANGINA USING A SIMPLE NEURAL
NETWORK ARCHITECTURE
Bulgiba AM 
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statistical methods (7). High sensitivity and specificity
levels (exceeding 80%) for cardiac ischaemia (a
mixture of AMI and angina) were also achieved with
feedforward neural networks on chest pain patients
with ECG and chemical cardiac markers (8,9) and
exceeding 90% (10) used neural networks to identify
patients with significant coronary artery disease and
reported positive predictive accuracy rates of 80% 
and negative predictive accuracy of 92% (11). How-
ever, little research has been made using neural net-
works in diagnosing angina although angina is probably
more prevalent than AMI in most developed countries.
Furthermore, attempts to build neural networks with-
out the use of any ECG and biochemical markers have
been made (12).
Due to the difficulty in diagnosing chest pain and the
importance of not missing an important disease like
angina where biochemical markers and ECG findings
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ABSTRACT: The aim of the study was to research the use of a simple neural network
in diagnosing angina in patients complaining of chest pain. A total of 887 records were
extracted from the electronic medical record system (EMR) in Selayang Hospital,
Malaysia. Simple neural networks (simple perceptrons) were built and trained using
a subset of 470 records with and without pre-processing using principal components
analysis (PCA). These were subsequently tested on another subset of 417 records.
Average sensitivity of 80.75% (95% CI 79.54%, 81.96%), specificity of 41.64% (95% CI
40.13%, 43.15%), PPV of 46.73% (95% CI 45.20%, 48.26%) and NPV of 77.39% (95% CI
76.11%, 78.67%) were achieved with the simple perceptron. When PCA pre-processing
was used, the perceptrons had a sensitivity of 1.43% (95% CI 1.06%, 1.80%), specificity
of 98.32% (95% CI 97.92%, 98.72%), PPV of 32.95% (95% CI 31.51%, 34.39%) and NPV
of 61.33% (95% CI 59.84%, 62.82%). These results show that it is possible for a simple
neural network to have respectable sensitivity and specificity levels for angina.
(JUMMEC 2006; 9(1): 39-43)
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may not be as helpful as AMI, this has become an area
where some form of decision-support with artificial
intelligence (AI) would be most helpful. It would thus
be possible to construct a tool or software to aid a
paramedic or even the public in diagnosing angina even
without the benefit of an ECG with a high degree of
probability (possibly exceeding 80%).
The objective of this study was to assess the sensiti-
vity, specificity, positive and negative predictive values
of simple (single-layer) perceptrons in chest pain
diagnosis with respect to the diagnosis of angina. It is
also aimed at how far one could use perceptrons in a
screening tool that could be used by paramedics or
even the public in diagnosing angina.
Materials and Methods
Source of data 
The data set was obtained from Selayang Hospital, a
tertiary level hospital in Malaysia. Permission to use
this data for this study was obtained from the Ministry
of Health, Malaysia. All records of adult patients (18
years or older) seen in the Emergency Department
for non-traumatic chest pain from 20 August 1999
(when the hospital opened) to 9 August 2002 and
clerked using the chest pain clerking form were
selected for this study.As this form was used for chest
pain suspected to be of cardiac origin, the number of
patients clerked using this form was low and the
proportion of angina patients clerked using this form
was high. Both stable and unstable angina were
included as angina as the diagnosis was not clearly
stated in many cases.The diagnosis on discharge was
used as the definitive diagnosis.
Data cleaning and pre-processing 
Data cleaning and pre-processing were performed
before the neural networks were constructed. This
involved accuracy checking, treatment of missing
values, recategorization and recoding of fields and
feature construction.The data was split into two sets;
a training set and a test set by random sampling.The
training set comprised 470 records while the test set
contained 417 records.The training set had 187 cases
of angina and the test set, 161 cases of angina.Table 1
shows the input variables in the data set.
Experimental methods
The single neuron, single-layer perceptron was used
for all experiments. The diagnosis on discharge was
used as the definitive diagnosis.This is the diagnosis as
confirmed by specialist physicians after taking into
consideration ECG readings and other laboratory
investigations.
All perceptrons were trained over a maximum of
1,000 epochs for each combination of input and
target.The perceptrons were then tested on the test
set. This process was repeated until ten perceptrons
had been trained and tested.Weights were initialized
randomly and reinitialized every time the network was
trained, so no two networks had the same weights.
Matlab 6.5 was used to build, train and test the per-
Group Fields
Demographic Age, citizen, race, sex, marital status
Nature of chest pain Location, onset, pattern, quality
Radiation of pain Jaw, left arm, laterally, neck, locally, other parts
Relieving factors Leaning forward, sitting up, GTN, rest, other means
Aggravating factors Posture, meals, coughing, inspiration, exertion
Associated heart/lung symptoms Cough, dyspnoea, oedema, orthopnoea, palpitations
Other associated symptoms Collapse, headache, dizziness, fever, numbness, nausea, sweating,
vomiting, fainting
Cardiac risk factors Age >40, diabetes mellitus, family history, hypertension, physical inactivity,
obesity, smoking, known case defaulted treatment, known case on
treatment, high cholesterol levels
General examination Pulses, pulse rate, respiratory rate, systolic BP, diastolic BP
Heart/lung examination factors Air entry, breath sounds, chest expansion, chest wall, crepitations,
heart sounds, JVP, percussion, pleural rub, praecordium, rhonchi
Other examination factors Abdomen, central nervous system (CNS), eye, face
Table 1. Input variables
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Perceptrons trained using the original data managed a
respectable mean sensitivity level of 80.75% (95% CI
79.54%, 81.96%). This contrast significantly with the
perceptrons trained using PCA-processed data, which
only managed a dismally low sensitivity of 1.43% (95%
CI 1.06%, 1.80%). The difference between these two
groups was not only statistically significant but also
clinically significant. In contrast, the specificity levels
were reversed between the two groups, with the per-
ceptrons trained using PCA-processed data managing
a very high specificity level of 98.32% (95% CI 97.92%,
98.72%) compared to the low specificity of the per-
ceptrons trained using the original data (41.64%; 95%
CI 40.13%, 43.15%). Despite the difference in the
sensitivity and specificity results, the PPV and NPV
levels were significantly better for perceptrons trained
using the original data. The PPV for the perceptrons
trained on the original data was 46.73% (95% CI
45.20%, 48.26%) while the PPV for the PCA group was
32.95% (95% CI 31.51%, 34.39%). NPV for the per-
ceptrons trained on the original data was 77.39% (95%
CI 76.11%, 78.67%) while the NPV for the PCA group
was 61.33% (59.84%, 62.82%). In general, the variability
in test accuracy, sensitivity and specificity levels were
much less for perceptrons trained on PCA-processed
data compared to those trained on the original data as
reflected by their much tighter confidence intervals.
Limitations
There are a few limitations to these experiments.The
single-layer perceptron is limited in what it can do and
while it is ideal for problems that have a binary output
like a diagnosis, it has some limitations in the amount of
information it can conceivably process. These percep-
trons have not been tested on a real-time basis but
there is no reason to think that it might not work given
that it worked on the 417 records (test set) that it had
never seen before.This study also did not evaluate all
potential patients with ischaemia because it was
confined to patients with chest pain in the Emergency
Department and thus did not deal with those suffering
from silent ischaemia. Finally, this study was carried out
at a single institution and one may need to corroborate
with patients from different locations.
ceptrons. Only patient-reportable factors and exami-
nation factors were used in this study as the aim was
to investigate, how well the perceptron would be able
to diagnose the disease without any investigation
results to rely on (Table 1).
After using the original data to train the perceptrons,
principal components analysis (PCA) was used to
reduce the dimensions of the input vectors.The data
was thus pre-processed and the perceptrons were
retrained and retested. Only input data that con-
tributed to more than 0.5% of the total variation in
the data set were retained.
The results were pooled for each group by the type 
of pre-processing (10 perceptrons for each group) 
and outcome measures with 95% confidence intervals
were calculated.
Statistical analysis
Sensitivity and specificity (13), as well as positive and
negative predictive values (14) with 95% confidence
intervals were calculated using standard formulas.The
use of a large sample size by pooling the results, is not
new (9) and was made in order to obtain a more re-
presentative picture of the perceptron performance.
This also avoids the problem of confidence intervals
exceeding 100% due to small sample sizes (15). Con-
tinuity correction was used for all calculations of
sensitivity, specificity, positive and negative predictive
values.
Results 
The performance of the angina perceptron is displayed
in Table 2. The training set had 187 cases of angina
while the test set had 161 cases of angina.There was
no significant difference in training time using the
original data and data that had been pre-processed
using PCA over 1000 epochs.There was a significant
difference in the mean MSE of the two groups with the
original data having slightly higher average MSE (0.421;
95% CI 0.402, 0.439) compared to the PCA group
(0.368; 95% CI 0.354, 0.382) but neither of the MSEs
reduced to zero.
Performance measure Mean without PCA (95% CI) Mean with PCA (95% CI)
Sensitivity (%) 80.75 (79.54, 81.96) 1.43 (1.06, 1.80)
Specificity (%) 41.64 (40.13, 43.15) 98.32 (97.92, 98.72)
PPV (%) 46.73 (45.20, 48.26) 32.95 (31.51, 34.39)
NPV (%) 77.39 (76.11, 78.67) 61.33 (59.84, 62.82)
Table 2. Angina perceptron performance
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Discussion
There has been some work with multi-layer percep-
trons in chest pain diagnosis and some workers have
shown some good results with these (9,10,16). How-
ever, most of the work has had to use ECG and
biochemical markers and none have used the simple
perceptron, perhaps as it is believed that it is not
capable of a complex and non-linear process of diag-
nosing a disease like AMI or angina. Attempts were
made for a neural network using just patient-
reportable factors and without the use of ECG and
biochemical markers (12). It was shown that some
uses could be made from the single-layer perceptrons.
These perceptrons have the advantage of the hard-
limit function and are relatively simple to implement.
The advantage is that their relative simplicity makes
them less useful where the input data is abstract and
they may be unable to “learn” the associations
between input and output well enough to be accurate.
The author is encouraged by the sensitivity of 80.75
(95% CI 79.54%, 81.96%) obtained without PCA
processing. Unfortunately, when PCA was used to pre-
process the data, it reduced the sensitivity greatly.
However, it improved specificity and made the percep-
trons consistently more specific compared to the per-
ceptrons trained without PCA pre-processing. One
possible explanation for this is that PCA reduces the
amount of information needed for the perceptron to
make a positive diagnosis and made it unable to differ-
entiate between a positive and negative diagnosis. It
would thus tend to label something as being no
different from another negative diagnosis. Thus, the
perceptron was able to more easily recognize what is
not angina rather than what is. Herein probably lies the
limitation of the perceptron in pattern recognition. A
perceptron can only represent linearly separable
functions and are thus not suitable for many functions
which are not linearly separable. PCA removes much
of the information which is necessary for the per-
ceptron to perform its function properly. However,
PCA does have one benefit. It reduces the variability of
the perceptron’s performance and makes it far more
predictable as far as specificity is concerned.
Conclusion
It seems difficult to come up with a perceptron which
is both highly sensitive and highly specific. This is not
surprising, as studies have shown similar findings with
regards to the balance in sensitivity and specificity (5).
Where sensitivity is raised, specificity can be expected
to fall as more false positive cases are identified.
Research has also shown high sensitivity and specificity
levels occurring at the same time (9). To expect the
perceptron to achieve sensitivity and specificity
greater than 80 per cent at the same time appears to
be beyond the single-layer perceptron especially
where there are no ECG and biochemical readings 
to help the perceptrons. In theory, the use of a 
2-perceptron system (where one perceptron is
trained with PCA and the other is trained without
PCA) with the results of both evaluated by a fuzzy
inference engine may be able to solve this problem,
but it is probably just easier to use a more sop-
histicated multi-layer neural network instead.
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